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INTRODUCTION 
Pregnancies are complicated by Hypertensive disorders  of about  5-10% and along with  
hemorrhage, sepsis and fetal growth restriction constitutes a triad contributing to maternal 
morbidity and mortality
1,2
. Hypertensive disorders in pregnancy  vary from mildly elevated 
blood pressure to severe hypertension with multi organ dysfunction. Of these disorders the 
preeclampsia syndrome , either alone or superimposed on chronic hypertension and its associated 
maternal mortality is the most dangerous and it accounts for 16% and is preventable
3
. 
The incidence of preeclampsia varies between 8-10% of  all pregnancies. In nulliparous 
woman, the incidence of  preeclampsia ranges between 2% and 7% (who conceive with Assisted 
Reproductive technology).This is responsible for 29,000 maternal deaths per year world wide.
4,5 
There is 5-fold increase in perinatal mortality in pre-eclampsia due to iatrogenic 
prematurity, respiratory distress syndrome and neonatal intensive admission 
6,7
. 
In India, Incidence of hypertensive disorders in pregnancy is 5.38%,while  preeclampsia 
and eclampsia accounted for 44% and 40% complications respectively.Maternal and perinatal 
deaths have been reported in 5.5% and 37.5% of deliveries
8
. 
Intensive maternal and fetal monitoring in such high risk patients would lead to an earlier 
diagnosis of the clinical signs of the disease and the associated fetal growth restriction and avoid 
the development of serious complications such as placental abrupton , eclampsia , Intrauterine 
death through such interventions as the administration of antihypertensive medication and early 
delivery. Modern antenatal care provision is focussed on a risk – based approach to monitoring 
for adverse pregnancy outcomes such as preeclampsia ,fetal growth restriction, placental 
abruption, still birth and pregnancy outcome of baby. Early identification of the high-risk group 
2 
for the development of adverse pregnancy outcome is also important for future studies 
investigating the potential role of pharmacological interventions starting from the first trimester 
to improve placentation and reduce the prevalence of the disease. Several prophylactic therapies 
(anti-oxidant, vitamins, folic acid supplementation and aspirin) have so far tried to prove its 
efficacy in the prevention of preeclampsia in healthy nulliparous groups. 
The term Gestational Hypertension used now to describe any form of new onset 
pregnancy related hypertension. 
Antenatal outcome can be improved  by early identification of pre-eclampsia by alerting 
the clinicians to the need of therapeutic prophylaxis and additional surveillance later in 
pregnancy, thus an increase in perinatal surveillance with significant decline in maternal and 
fetal  mortality and morbidity which is associated with pre-eclampsia and eclampsia.  
Impaired placentation with abnormal blood flow velocity and resistence in placental 
vessels is associated with pre-eclampsia and fetal growth restriction. Prediction of hypertensive 
disorders and associated adverse outcomes  by Ultrasonography plays an important role.  
             Uterine artery Doppler waveform analysis has been extremely studied in the second 
trimester of pregnancy as a predictive marker for the late development of pre eclampsia and  fetal 
growth restriction. The use of Doppler interrogation of this vessel in the first trimester has gained 
momentum in recent years. In normal pregnancy ,the feto placental circulation acts as a low 
resistance system unit. Thus blood velocity waveforms in umbilical artery show continuos 
forward flow throughout the cardiac cycle. Impaired placental perfusion ,one of the hallmarks of 
preeclampsia, can be assessed by measuring flow waveforms ratios or by detecting diastolic 
notching of the uterine and umbilical vessels. According to the National Institute for Clinical 
3 
Excellence guidelines on routine prenatal care recommending that at the first prenatal visit a 
woman‟s level of risk for adverse pregnancy outcome should be evaluated so that a plan for her 
schedule of prenatal visits can be formulated. There is no proven effective method for the 
prevention of PE.  
Currently  there is no treatment which can prevent all cases of preeclampsia, there is 
evidence that low dose aspirin started early in pregnancy have some role in reducing the 
incidence of adverse pregnancy outcome in significant no of cases now.. Prophylactic aspirin 
reduces early on PE and preterm delivery by 10%.
9 
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AIM AND OBJECTIVE 
Aim: 
 The aim of the study is to evaluate the first trimester uterine artery Doppler in the 
prediction of the development of adverse pregnancy outcome. 
Objectives: 
 Correlation of uterine artery Doppler in the first trimester with adverse pregnancy 
outcome. 
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MATERIALS AND METHODS 
Source of Data 
This is a prospective screening study for women attending antenatal clinic during 11-13 
weeks + 6 days of gestation in PSG IMSR, Coimbatore. In this visit, women will have an 
ultrasonogram for the following reasons:  
(1) to confirm gestational age from the measurement of the fetal crown-rump length 
(CRL) 
(2) to diagnose any major fetal abnormalities 
(3) to measure fetal nuchal translucency thickness and nasal bone, as part of the 
screening for chromosomal abnormalities.  
(4) Along with this Informed consent will be obtained and Uterine artery Doppler 
Pulsatile Index(PI) will be measured by Transabdominal or Transvaginal colour 
Doppler. 
Methodology of the study:  
Study Design: Prospective longitudinal Observational  study. 
Sample size: 150 no‟s ( Control – 75 and case group – 75) 
All women meeting inclusion criteria during jan 2016 – jan 2017 
 With Reference Study : Evaluating the optimal definition of abnormal First – 
Trimester. Uterine Artery Doppler Parameters to Predict Adverse Pregnancy 
Outcomes. 
                 [From -  J Ultrasound Med. 2015 jul ;34(7);1265-9,doi;10.7863/ultra.34.7.1265] 
6 
Calculation: 
n = 4 x p x q / d2 
P = 45 
Q = 100 – p 
100-45 = 55 
d   =  precision (20% of 45) 
d   = 20 x 45 / 100  
d   = 9 
n  =  4 x 45 x 55/ 9 x 9                      
n  =  122 (calculated sample) 
Place:  Department of Obstetrics and Gynaecology – OPD 
PSG Institute of Medical Science and Research Centre, Peelamedu , Coimbatore 
Duration:  1 Year ,  1
st
 Jan 2016 – 1st Jan 2017 
  Method: This is a Hospital based prospective study. 
Inclusion Criteria 
 All pregnant women attending antenatal check up in PSG IMSR  
 Between 11 -  <13wks  + 6 days will be included. 
 
7 
Exclusion Criteria  
 Past history of preeclampsia 
 Chronic hypertension 
 Twins   
 Missed abortion  
 Major Fetal anomaly which are incompatible with life  
 Not consenting. 
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REVIEW OF LITERATURE 
Hypertensive disorders of pregnancy are the most common medical complication in 
pregnancy with high incidence of maternal and perinatal morbidity and mortality. 
DEFINITION OF HYPERTENSION:  
Currently, the following thresholds used by NHBPEP and the ACOG to define 
hypertension is used by most of the international organizations and national bodies.
10,11
 
Hypertension is defined as, 
 Systolic blood pressure of >/= 140 mmHg and or  
Diastolic Blood pressure >/=90 mmHg (korotkoff 5), on at least two occasions, four to 
six hours apart within a one week period maximum. 
Diastolic pressure is determined by disappearance of sound(koratokoff phase 5). 
 Elevation of > 30mmHg of systolic or more than 15mmHg of diastolic, even the absolute 
values are <140/90 mmHg is no longer recommended as a criteria (because no evidence 
to justify that these women have increased risk of adverse pregnancy outcome).
12
 
 Blood pressure should be measured by appropriate cuff size (cuff should encircle 80% or 
more of the arm and cover 2/3
rd
 of the length of the arm) 
 Correct positioning of the patient is important in BP assesement, Patient should be seated 
resting for 5 mins, with the arm at the level of chest,legs not crossing and not talking. 
 
 
 
9 
DELTA HYPERTENSION – CONCEPT 
A sudden rise in mean arterial pressure (MAP) later in pregnancy even if blood pressure 
is <140/90 mm of hg is known as “delta hypertension”. This is the reason for eclamptic seizures, 
while women is still considered as normotensive, so close surveillance is needed. 
Figure 1: Delta hypertension graphical representation 
 
Patient A has BP near 20
th
 percentile throughout pregnancy . 
Patient B has a similar pattern till 32 weeks but then begins to increase. 
Even though she is at 75
th
 percentile but still considered normotensive. 
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CLASSIFICATION OF HYPERTENSIVE DISORDERS OF PREGNANCY 
Based on International society for the study of Hypertension in Pregnancy (ISSHP), hypertensive 
disorders in pregnancy is classified into following types 
1. Gestational hypertension 
2. Pre-eclampsia (PE)  
3. Eclampsia syndrome 
4. Chronic hypertension – Essential / Secondary 
5. Pre-eclampsia superimposed on chronic hypertension 
DIAGNOSTIC CRITERIA OF HYPERTENSIVE DISORDERS COMPLICATING 
PREGNANCY: 
1. GESTATIONAL HYPERTENSION 
 BP > 140/90 after 20 weeks in a previously normotensive patient on two 
successive measurement four to six hours apart. 
  Proteinuria - Absent 
 BP  returns to normal < 12 weeks postpartum (within 3 months) 
 Final diagnosis made only postpartum 
 May have other signs or symptoms of preeclampsia like epigastric discomfort 
or thrombocytopenia. 
Most common hypertensive disorders of pregnancy with prevalence of 6-15% in 
nulliparous and 2-4% in multiparous
14
. It is previously known as „”Pregnancy Induced 
Hypertension”15. It can be mild or severe (if BP > 160/110 mmHg).There is higher incidence of 
11 
preterm birth and small for gestational age newborns for severe gestational hypertension than 
mild ones
.16
. 
2. PREECLAMPSIA 
Hypertension with associated proteinuria > 0.3g/l in a 24 hour urine collection or 1+ by 
qualitative urine examination, after 20 weeks of gestation.It is precursor for potentially lethal and 
severe disease(eclampsia) on its own.Over the several years,”the treatment “is delivery. 
Definition – New onset hypertension with BP >/=140/90 mm of Hg with new onset proteinuria 
after 20weeks in a previously normotensive patient. 
Note – Edema is been removed from the definition, because it is too common a clinical finding 
during pregnancy to be clinically significant. 
ACOG (2013)-released guidelines for diagnostic criteria for PE. 
 Mild PE is defined as “PE without severe features” 
 Severe PE is defined as “PE with severe features” 
 Proteinuria  (>5gm) has been eliminated from the list of features defining severe features, 
due to lack of evidence that quantity of protein is associated with significant change in 
outcome.In its absence PE also be defined as new-onset hypertension with other signs of 
multisystem involvement. 
 FGR is  removed from the list of features defining severe disease, as guidelines state that 
management of FGR is the same regardless of diagnosis of PE. 
 Based on the period of onset, PE is classified into early-onset and late-onset.Early onset 
PE is defined as development of PE before 34 weeks of gestation,which affects 1% of 
12 
population.
18
.Late onset is defined as development of PE after 34 weeks of gestation .As 
compared to late onset PE, early onset is associated with increased maternal mortality and 
adverse perinatal outcome such as fetal growth restriction, intensive care, preterm care.
19
 
A. Mild preeclampsia 
 BP >/=140/90 mmHg after 20 weeks gestation. Systolic BP < 160 mmHg and 
diastolic BP< 110 mmHg on two successive measurements four to six hours apart 
 Proteinuria:  Present (>0.3gram in 24 hour sample or 1 + or greater in a random 
sample, 30mg/dl) 
 No symptoms, signs or laboratory features of severe preeclampsia 
B. Severe preeclampsia 
 BP >/= 160/110 mmHg 
 Proteinuria: None to present ( > 5 gram in a 24 hour sample or >3 + on two random 
urine samples collected atleast 4 hours apart)  
 Headache: Present 
 Visual disturbances: Present 
 Upper abdominal pain: Present  
 Oliguria: Present 
 Convulsions: Present 
 Serum creatinine: Elevated 
 Thrombocytopenia: Present 
 Serum transaminase level : Marked 
 Fetal growth restriction: Present 
 Pulmonary edema: Present 
13 
Table 1 – Severity of PE Classification 
 
3. ECLAMPSIA 
Seizures that cannot be attributed  to other causes in a woman with pre eclampsia. It is a 
severe form of PE. Characterized by sudden onset of generalised tonic- clonic convulsion or 
coma in pregnancy or postpartum which is unrelated to other cerebral conditions. Based on the 
time of convulsions, it is designated as antepartum (38-53%), intrapartum(15-21%) and 
postpartum(11-44%) eclampsia.
20
 
4. CHRONIC HYPERTENSION 
 BP>/= 140/90 before pregnancy or diagnosed before 20 weeks gestation not 
attributable to gestational trophoblastic disease. 
 Hypertension first diagnosed before 20 weeks gestation and persistent after 12 
weeks postpartum 
 Proteinuria – absent. 
 It complicates 0.5 to 3% of all pregnancies. It can be essential (90%) or secondary 
(10%  )hypertension. 
14 
TABLE 2 – CAUSES OF CHRONIC HYPERTENSION 
1.Primary or essential hypertension 
2.Secondary hypertension 
 Endocrine  
- Diabetes with vascular involvement 
- Hyperthyroidism 
- Congenital adrenal hyperplasia-Primary Aldosteronism 
- Cushing Syndrome 
 Tumours 
- Neuro blastoma 
- Pheochromocytoma 
- wilson‟s tumour 
 Renal 
- Renal artery Stenosis 
-Renal parenchymal disease (Adult polycystic disease, Reflex nephropathy,                  
Glomerulonephritis) 
 Collagen vascular disease 
- Scleroderma  
- Systemic Lupus erythematosis 
 Heart 
-Coarctation of aorta 
 
.     
15 
5. SUPERIMPOSED PRE-ECLAMPSIA 10 
 New onset proteinuria defined as the urinary excretion of 0.3 grams protein or 
greater in a 24 hour specimen in women with hypertension but no proteinuria 
before 20 weeks gestation. 
 Development of imminent symptoms or platelet count < 100,000 and abnormal 
liver enzymes.  
 About 30% of pregnant women  with chronic hypertension develop PE.It usually 
manifest in early pregnancy than pure PE and is more severe. 
ATYPICAL PREECLAMPSIA: 
In some woman, preeclampsia and even eclampsia may develop in the absence of either 
hypertension or proteinuria. TABLE 3 – Criteria for Atypical PE 
CRITERIA FOR ATYPICAL PREECLAMPSIA 
 Gestational hypertension plus one or more of the following 
o Symptoms of preeclampsia 
o Hemolysis 
o Thrombocytopenia( < 100,000/ cu.mm) 
o Elevated liver enzymes: Two times the upper limit of the normal value for 
Aspartate transaminase (AST) and Alanine transaminase (ALT) 
 Gestational proteinuria plus one or more of the following 
o Symptoms of preeclampsia 
o Hemolysis 
o Thrombocytopenia 
 Early signs and symptoms of preeclampsia-eclampsia at <20 weeks  
 Late postpartum preeclampsia-eclampsia (>48 hours postpartum ) 
16 
ETIOPATHOGENESIS OF PRE-ECLAMPSIA 
            Gestational hypertension is more likely to develop in a woman with the following Risk 
Factors 
 Women are at increased risk for PE if they have 1 high risk factor or more than 1 
moderate risk factor for PE.  
High Risk Factors: 
 Type 1 or Type 2 diabetes 26 
 Chronic hypertension26 
 Chronic kidney disease26 
 Auto immunse disease-APLE/SLE26 
 Hypertension in previous pregnancy25 
Moderate Risk Factors: 
 First time exposure to chorionic villi – first pregnancy. 
Chorionic villi is essential need not to be intra uterine.
25
 
 Age - >40yrs or more25 / < 20 years. 
 Pregnancy interval of > 10years 
 Body Mass Index (BMI) of >35kg/m2  at first visit, 
(risk increases for every increase of 5-7kg/m
2 
in pre – pregnancy BMI.21) 
 Family history 25,26 
  multiple pregnancy20  
 Change of new partner 
17 
 Partner who fathered a pre-eclamptic pregnancy in another woman 
 Pregnancy due to donor insemination 
Note – Smoking regulates adrenomedullin expression, which regulates volume homeostasis. 
 Hypertensive disorders are more likely to develop in women with following 
characteristics. 
1) First time exposure to chorionic villi. 
2) Those who are exposed to superabundance of chorionic villi, as seen in molar pregnancy 
or multiple pregnancy. 
Note – fetus is not a requisite for the development of PE.Chorionic villi is need to be 
intrauterine. 
3) Have pre-existing conditions of endothelial cell activation or inflammation such as 
diabetes or renal or cardiovascular disease 
4) Genetically predisposed to hypertension developing during pregnancy24,25 
ETIOLOGY 
The mechanism by which preeclampsia occurs is not clear, and numerous 
maternal, paternal, and fetal factors have been implicated in its development.This 
disorder has a potential to involve all organs in the body. 
Mechanisms currently considered important are 
 Defective placentation 
 Placental ischaemia 
 Endothelial cell dysfunction 
18 
 Immunological maladaptive tolerance between paternal, maternal and fetal tissues  
 In normal pregnancy maternal maladaptation to cardiovascular or inflammatory 
change 
 Genetic factors including epigenetic influences and inherited predisposing genes. 
 Nutritional factors  
 
ABNORMAL TROPHOBLASTIC INVASION 
         Normal placental development requires that cytotrophoblastic invasion in to the maternal 
spiral arterioles. Placenta receives it blood supply from numerous uteroplacental arteries that are 
developed by the action of migratory interstitial and endovascular trophoblasts into the walls of 
spiral arterioles(Remodelling). This transforms the uteroplacental arterial bed into a large 
capacitance ,low- resistance, low-pressure, high-flow system. This spiral arterioles remodelling  
starts in the late first trimester and ends by 18- 20 weeks of gestation resulting in replacement of 
the endothelium and the muscular tunica media. The veins are invaded only superficially. Thus 
PE has been hypothesized as a “two stage disorder”. 
  
19 
FIGURE 2 – Abnormal Trophoblastic Invasion and Outcome 
 
In pre-eclampsia there is incomplete trophoblastic invasion. Here the decidual vessels, but not 
the myometrial vessels, become lined with endovascular trophoblasts. The deeper myometrial 
arterioles do not lose the endothelial lining and musculoelastic tissue and their mean external 
diameter is only half that of corresponding vessel in the normal placenta. This restriction of 
normal physiological changes leads to restricted placental flow,which becomes more critical with 
adavancing gestation. The vessels affected by atherosis develop aneurysmal dilatation or 
obstruction of lumen by atherosis may hinder the placental blood flow, which lead to infarcts, 
patchy necrosis and damage to intracellular synctiotrophobalst . Infact, studies have shown the 
degree of incomplete trophoblatic invasion of the spiral arteries is directly associated with the 
severity of pregnancy induced hypertension.
34
 
20 
These abnormally narrow spiral arteriolar lumen are likely to impair the placental blood 
flow. This leads to diminished perfusion and hypoxic environment eventually lead to release of 
placental debris or microparticles that incite an inflammatory response. 
Defective placentation is postulated to further cause susceptible woman to develop 
gestational hypertension, preeclampsia syndrome, preterm delivery, a growth restricted fetus 
and/or placental abruption.  
FIGURE 3 – Normal and Abnormal Trophoblastic Invasion Of Spiral Arteries 
 
Trophoblastic invasion/differentiation entails changes in the expression of certain 
cytokines, adhesion molecules, extracellular matrix molecules, metalloproteinase, and class 1b 
major histocompatibility complex molecule and histocompatibility leucocyte antigen (HLA –G)  
21 
           Placental implantation with abnormal trophoblastic invasion of uterine vessels  leads to 
myometrial segments of spiral arterioles are left with musculo elastic structure,thereby 
responsive to hormonal substances.
35
 
IMMUNOLOGIC FACTORS 
Loss of immune tolerance to paternally derived placental and fetal antigens is another 
cause accounted for preeclampsia syndrome. Immunological factors may play an important role 
in the development of pregnancy induced hypertension. This phenomenon in pregnancy induced 
hypertension include absence of blocking antibodies, decreased cell mediated immune responses, 
activation of neutrophils and involvement of cytokines. An aberrant immune reaction between 
fetal trophoblast with maternal tissue in the placental bed is a basic factor in the cause of 
pregnancy induced hypertension, supported by the findings that this syndrome most often affects 
first pregnancy. Incidence is also increased by change of partner and in a subsequent pregnancy 
after birth control methods that prevent sperm exposure. Women who develop pregnancy 
induced hypertension have decreased proportion of helper T cells (Th 1) in early second 
trimester, compared with those who remain normotensive. The Th 1/Th 2 imbalance may be 
mediated by adenosine, found in higher concentration in pregnancy induced hypertension 
women. The helper lymphocytes secrete cytokines that promote implantation and their 
dysfunction leads to pregnancy induced hypertension.
37,38
  
NUTRITIONAL FACTORS: 
In many studies have shown a correlation between dietary deficiencies and the incidence 
of PE. Diet lack in antioxidants enzymes and antioxidant nutrients, including carotenoids, alpha 
–tocopherol and thiols are the primary agents against oxidative stress and free radical damage . 
22 
These will protect the endothelial cell membrane against free radical produced. When this 
protective mechanism is lost , the products of lipid peroxidation increase with fall in antioxidant 
carotenoids. This imbalance leads to oxidative stress and tissue injury.
41,42
 
Vitamin C and Vitamin E supplementation between 16 – 22 weeks of gestation decrease 
the incidence of pregnancy induced hypertension by approximately 50%.
43
 In contrast the same 
supplementation in high risk pregnant women between 14-22weeks gestation with low 
nutritional status does not prevent PE.
44
 
 Incidence of preeclampsia was doubled in woman whose daily intake of ascorbic acid 
was less than 85mg, low dietary calcium intake. 
Lycopene is not converted to Vitamin A; hence it may be entirely available for 
antioxidants. Its supplementation in studies has been shown evidence of decreased incidence of 
pregnancy induced hypertension and fetal growth restriction by 51.4% and 49.3% respectively.
45
 
ENDOTHELIAL CELL ACTIVATION :   
Defective placentation leads to an inflammatory state leads to the release of cytokines 
such as interleukins which may contribute to the oxidative stress associated with preeclampsia. 
 Other consequences of oxidative stress include production of lipid laden macrophage foam cells 
seen in atherosis and activation of microvascular coagulation manifest by thrombocytopenia and 
increased capillary permeability manifest by edema and proteinuria.
36
 
  
23 
GENETIC FACTORS 
Familial predisposition for pregnancy induced hypertension has been recognized, single 
gene model and polygenic inheritance has been suggested. 60% concordance in monozygotic 
female twin pairs has been reported by a Swedish study. Some have reported a HLA-DR4 
association with proteinuria in pregnancy induced hypertension. A number of single gene 
mutation and inherited thrombophilia‟s may predispose to pregnancy induced hypertension. 
Polymorphisms of the genes for Tumour Necrosis Factor, lymphotoxin-alpha and interleukin-1 
have been studied with varying results.
39
 Genes with possible associations with PE syndrome are 
mentioned in table 4 .  
Table 4 – Genetic Factors Responsible For PE 
Gene polymorphism Function affected 
MTHFR(C677T) Methylene tetrahydrofolate reductase 
F5(Leiden) Factor Vleiden 
AGT(M235T) Angiotensinogen 
HLA(Various) Human leukocyte antigens 
NOS3(Glu 298 Asp) Endothelial nitric oxide 
F2(G20210A) Prothrombin( factor II) 
ACE(I/D
at
Intron 16) Angiotensin-converting enzyme 
CTLA4 Cytotoxic T-lymphocyte-associated protein 
LPL Lipoprotein lipase 
SERPINE1 Serine peptidase inhibitor 
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PATHOGENESIS 
It is characterised by vasospasm, endothelial cell damage resulting in activation of coagulation 
system. 
1. Endothelial cell activation leads to vascular constriction with increased resistance and 
subsequent hypertension. Decreased  blood flow due to mal-distribution and ischemia of 
the surrounding tissues causes  necrosis, hemorrhage and end organ disturbances 
characteristic of the syndrome. 
2. Vasospasm –   
     Nitric acid is a potent vasodilator, synthesized from L-arginine by endothelial cells. It 
maintains the normal low pressure vasodilated state of feto placental circulation in 
humans. Damaged or activated endothelial cells produce very less nitric oxide and 
produce substances that promote coagulation and increase the sensitivity to vasopressin. 
     Increased pressor responses ( Angiotensin 2) 
     Prostaglandins - Endothelial prostacyclin (PGI2 – a vasodilator) production is 
decreased in preeclampsia and Thromboxane A2(TXA2 – vasoconstrictor and platelet 
aggregator) secretion by platelet is increased. This alteration in thromboxane : 
prostacyclin ratio favours an increased sensitivity to angiotensin ultimately leading to 
vasoconstriction. If PGI2 > TXA2 ->Vasodilator ->No hypertension. In pregnancy 
induced hypertension, PGI2 <TXA2 ->Vasoconstriction ->hypertension.
37
 
     Endothelial cell injury causes decrease in the nitric oxide production. 
       3. Endothelins - Plasma Endothelin -1 levels are increased in normotensive pregnant 
woman , but woman with preeclampsia have even higher levels. It is produced by human 
endothelium. These alpha 1-amino acid peptides are potent vasoconstrictors;
46,47 
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4. Circulating angiogenic factors - Imbalance between the Angiogenic and Anti-
angiogenic factors. Trophoblast of woman destined to develop preeclampsia over 
produces atleast two antiangiogenic peptides that enter the maternal circulation- Soluble 
Fms- like tyrosine kinase 1 (sFlt-1), soluble endoglins (sEng). 
Figure 4 – Balance between Pro angiogenesis and  Anti Angiogenesis in PE -  Normal 
 
Vascular endothelial growth factors (VEGF) are endothelial specific growth factors plays 
a key role in promoting angiogenesis; placental growth factor (PLGF) is another member of 
VEGF family that is made predominantly in placenta. Activity of VEGF is mediated by 
interaction with two high affinity receptor tyrosine kinases: Kinase insert domain region (KDR) 
and fms like tyrosine kinase-1 (flt-1).These are expressed an endothelial surface. Alternative 
splicing of flt-1 results in production of sflt-1; this cannot attach to cell membranes and is 
secreted in to the maternal blood. It can antagonize VEGF and PLGF by binding to it and 
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preventing its interaction with endogenous receptors. Excess sflt-1 production is seen in 
pregnancy induced hypertension/PE placentas, which creates an antiangiogenic state and plays a 
causal role in the pathogenesis of maternal syndrome in pregnancy induced hypertension/PE. 
49
 
Figure 5 – Mechanism of  sFlt-1 and sEng in causing PE. 
 
Soluble endoglin(sEng) is derived from placenta blocks endoglin, which is a surface 
coreceptor for the transformin growth factor β(TGFβ) family. sEng inhibits TGFβ from binding 
to endothelial receptors and results in decreased endothelial nitric oxide-dependent 
vasodilation.
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 VEGF is known to stimulate angiogenesis as well as to promote vasodilation by 
increasing production of nitric oxide and prostacyclin, signalling molecules that are decreased in 
pregnancy induced hypertension/PE. PLGF is important in vasculogenesis and control of 
microvascular permeability.
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PREDICITON OF PREECLAMPSIA 
Measurement during early pregnancy – or across pregnancy – of various biological, 
biochemical, and biophysical markers implicated in the pathophysiology of preeclampsia has 
been proposed to predict the development. These testing strategies have poor sensitivity and poor 
positive predictive value for preeclampsia. Few tests are discussed below 
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1. Roll over test (Gant’s roll over test): It measures the hypertensive response to woman 
at 28 to 32 weeks who are resting in the left lateral recumbent position and then roll over 
to supine position. Increase in blood pressure (diastolic BP by 20mm of Hg) signifies a 
positive test. In preeclampsia the positive predicitive value was only 33%, negative 
predictive value was 92%..Sensitivity is 20% and specificity is 93%.
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2.  Serum uric acid – It is one of the early manifestation of PE. Plasma uric acid exceeding 
5.9 mg/dl at 24 weeks had a positive predicitive value for preeclampsia by 33%. It likely 
results from reduced uric acid clearance from diminished glomerular filtration, increased 
tubular reabsorption and decreased secretion. Sensitivity – 0-55%,specificity 77-95%.59 
3. Fibronectin : These high molecular weight glycoproteins are released from endothelial 
cells and extracellular matrix following endothelial injury. Increased plasma levels of 
fibronectin precedes the clinical signs of preeclampsia. The positive predicitive value was 
29% but negative predictive value was 98%. Sensitivity is 50-83% and specificity is 43-
94%.
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4. Mean arterial pressure measurement: 
 Elevated mean arterial pressure at least 85-90 mm of Hg in second trimester has 
been reported to have widely varying predictive ability. 
 The sensitivity of the screening test was 22.9% , specificity 92.5% , positive 
predictive value 25.0% and negative predictive value 91.7%.
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5. Provacative pressor tests: 
Three tests have been evaluated to assess the BP rise response to a stimulus. 
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6. Isometric exercise test(Hand-Grip test): 
The Hand-Grip test is positive when the systolic blood pressure increased 15 mmHg or 
more during isometric exercise or decreased 14 mmHg or more immediately after 
isometric exercise. The sensitivity, specificity, PPV and NPV are 81.8%, 68.4%, 20% 
and 07.5% respectively.
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7. Serum biomarkers of fetal- placental unit endocrine dysfunction: 
Several serum parameters have been proposed to predict PE. They include human 
chorionic gonodotropin(hcG), alpha-fetoprotein(AFP), estriol, pregnancy-associated 
protein A(PAPP A), inhibin A, activin A, placental protein 13(PP13), corticotropin-
releasing hormone, A disintegrin, ADAM-12 and kisspeptin. Newer ones are 
continuously added. Many studies have been done to evaluate the value of them in 
prediction of PE but none are proven beneficial. The prediction value of the PAPP-A, 
AFP and uE3 is 0.032, with the specificity and sensitivity of 98.93% and 70.59%, 
respectively. 
 
8. Microalbuminuria: 
Microalbuminuria is defined as excretion of albumin in urine at the rate of 30-
300mg/day. Studies are showing that there is increased incidence of PE with presence of 
microalbuminuria at booking visit. As a predictive test for PE, microalbuminuria has 
sensitivity, specificity, PPV and NPV of  88.9%, 67.9%, 22.2% and 98.3% respectively.
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9. Angiogenic and antiangiogenic factors: 
The imbalance between proangiogenic and antiangiogenic factors is related to PE 
pathogenesis. Serum levels of proangiogenic factors like VEGF and PIGF decrease 
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before clinical manifestation of PE, at the same time levels of antiangiogenic factors like 
sFlt-1 and sEng increase.
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The sensitivity, specificity, PPV and NPV of sEng is 62.1%, 56.8%, 52.9% and 65.6%  
respectively. The sensitivity, specificity, PPV and NPV of sFlt-1 is 44.8%, 67.6%, 52% 
and 61% respectively. The sensitivity, specificity, PPV and NPV of PIGF is 100%, 
47.2%, 60.4% and 100% respectively. The sensitivity, specificity, PPV and NPV of sFlt-
1/PIGF is 96.6%, 5.7%, 40% and 100%.
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 Their predictive accuracy is higher for early-
onset PE. 
10. Cell-Free Fetal DNA: 
The novel technology of cell-free fetal DNA (cffDNA)  testing in maternal serum is 
commonly used for prenatal aneuploidy screening but may demonstrate other predictive 
applications. Higher levels of cffDNA have been found in women who develop PE and 
are thought to be secondary to accelerated placental apoptosis from hypoxia and 
oxidative stress in placental insufficiency.
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Significantly elevated levels are seen in 
early-onset or severe PE and precede any clinical symptoms. 
Maternal ethnicity, BMI, and smoking status are known to affect cffDNA levels, but 
these confounding factors have not been adequately controlled for in earlier studies. 
Rolnik et al. demonstrated an increase in median total cff DNA and a decrease in median 
fetal fraction at 11–13 weeks in women who subsequently developed early-onset PE.64 
However, the results were not statistically significant once converted to multiples of 
median and adjusted for maternal characteristics, and the authors concluded that cffDNA 
levels are not predictive of PE in isolation. 
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11. Proteomic, metabolomic and transcriptomic markers: 
Study of serum and urinary proteins and cellular metabolites are the newer advances in 
the prediction of PE. Preliminary studies indicate that they may be useful. 
12. Oxidative stress: Increased level of lipid peroxide coupled with decreased activity of 
antioxidants is seen in woman with preeclampsia. Malondialdehyde is a marker of lipid 
peroxidation. Other markers are hyperhomocystinemia causes 3 to 4 fold risk of PE.  
13. Cytokines  
Elevated levels of various cytokines like some interleukins, Tumour Necrosis Factor – 
alpha and C-reactive protein are noted in woman with PE 
14. Biochemical markers: Due to inflammatory cascade, number of placental peptides are 
released like corticotrophin-releasing hormone, chorionic gonadotrophin, pentraxin 3 
(PTX-3), P-Selectin, pregnancy associated plasma protein A (PAPP-A) activin A and 
inhibin A. Elevated levels of antiangiogenic factors are associated with PE. 
 
15. UTERINE ARTERY DOPPLER VELOCIMETRY  
Doppler ultrasound of the uterine artery impedance in the first trimester has been used as 
an early screening for preeclampsia. Alteration in the uterine artery PI predicts the onset 
of the disease. 
Normally uterine artery PI decreases with gestation. The decrease in the impedance to 
flow with gestation is presumably the consequence of physiological trophoblastic invasion of 
maternal spiral arteries. 
31 
Many studies evaluated the worth of the  abnormal uterine artery doppler studies in 
prediction of PE both in first and second trimesters. In first trimester the sensitivity of 24% and 
PPV of 11% is reported by Gomez et al.
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 In second trimester sensitivity of 76.9%, a specificity 
of 52.9%, a PPV of 10.2%, and a NPV of 97.1%, respectively are reported in prediction of PE.
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ANATOMY OF UTERINE ARTERIES 
Uterus receives its blood supply from uterine and ovarian artery.        
Figure 6 – Anatomy of Uterine artery. 
 
Uterine artery arise from the anterior trunk of the internal iliac ( or hypogastric artery). It 
reaches the uterus at the level of internal os ,slides upwards spirally along the lateral border of 
uterus to the region of uterine cornua and finally anastomose with the ovarian artery. 
Uterine artery –> Arcuate –> Radial –> Basal –> Spiral and straight arterioles of the 
functional layer of endometrium.   
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Figure 7 – Anatomy of Uterine Artery(b) 
 
Ovarian arteries arise from the aorta, just below the level of the level of renal arteries. 
PHYSIOLOGY OF UTEROPLACENTAL CIRCULATION 
Placenta is a unique vascular organ that receives blood supply from both maternal and fetal 
systems. 
1. The maternal – placental (uteroplacental) circulation 
Here circulation starts with the maternal blood flow into the intervillous space through 
decidual spiral arteries. The inflow maternal arterial blood pushes deoxygenated blood 
into the endometrial and then uterine veins back to the maternal circulation. 
2. The fetal - placental (fetoplacental) blood circulation  
This allows the umbilical arteries to carry deoxygenated blood and nutrient depleted fetal 
blood from the fetus to the villous core to the vessels. The umbilical vein carries fresh 
oxygenated and nutrient rich blood circulating back to the fetal circulation. At term, 
maternal blood flow to the placenta is approximately 600-700ml per minute. The 
functional maternal-fetal exchange  takes place at terminal villi. 
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DOPPLER ULTRASOUND:  
Doppler ultrasound provides a non-invasive method for the study of fetal 
hemodyanamics. Investigation of the uterine and umbilical arteries gives information on the 
perfusion of the uteroplacental and fetoplacental circulation, respectively, while Doppler studies 
of selected fetal organs are valuable in detecting the hemodyanamic rearrangements that occur in 
response to fetal hypoxemia. 
Direct measurement of the uterine artery blood flow was obtained by means of 
electromagnetic technique.  
PRINCIPLE OF DOPPLER: 
The Doppler effect is defined as the observed changes in the frequency of transmitted 
waves when relative motion exists between the source of the wave and the observer. The 
frequency increases when the source and the observer move closer and decreases when they 
move apart.                 
Figure 8– Doppler Effect(a) 
 
This phenomenon bears the name of the discoverer, Christian Andrews Doppler, an 
Austrian mathematician and physicist in 1842. The change in frequency of the energy wave 
transmission is known as the Doppler frequency shift or simply the Doppler shift. 
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Figure 9 – Doppler Effect 
 
   fd = ft – fr : fd – is the Doppler shift frequency 
                     ft is the transmitted frequency 
                    fr is the received frequency. 
   The change in frequency of the energy wave transmission is known as the Doppler frequency     
shift or simply the Doppler shift. 
  The Doppler effect is observed irrespective of whether the observer or the source moves. 
 
DOPPLER VELOCIMETRY: 
Qualitative assessment: Achieved usually by analysing the waveforms or the colour 
distribution. Blood flow can also be qualitatively assessed by listening to Doppler signals. 
Quantitative assessment: Allows assessment of velocity. Doppler measurement can be 
considered reliable as long as the insonent angle is 60 degrees. Velocity measurements most 
commonly in pulsed Doppler are maximum peak systolic velocity, highest time averaged 
maximum velocity and minimum diastolic velocity. 
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Semi-quantitative assessment: The relationship between systolic and diastolic components of 
waveforms is evaluated and angle dependence which is important in quantitative measurements 
becomes less important. Commonly used indices available on most commercial scanners are  
1) Resistance index (RI) (Also called resistive index or Pourcelot‟s index)  
RI = (peak systolic velocity – end diastolic  velocity)/peak systolic velocity [(S-D)/S] 
2) Systolic /Diastolic ratio (S/D, sometimes called A/B ratio) 
3) Pulsatility index ( P/I) =(S-D)/A 
PI = (peak systolic velocity – end diastolic  velocity)/ time averaged velocity. 
Figure 10 – Doppler Indices 
 
These indices are all based on the maximum Doppler shift waveform. The PI takes slightly 
longer to calculate than the RI or S/D ratio because of the need to measure  the mean height of 
the waveform PI is a better index in obstetric Doppler because,  
 When diastolic velocity =0, RI will always be 1, whereas PI could be any value more  
than 1. So PI is more informative in such situations 
 PI takes the entire waveform into account and not just the maximum and minimum  
frequencies as in RI. 
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Doppler study of Uteroplacental circulation 
Using Doppler as a screening test, several studies have demonstrated an association of  
abnormalities in the flow velocity waveform of uterine arteries with the subsequent development   
of PE, fetal growth restriction(FGR), placental abruption and preterm delivery. 
The morphologic changes in the uterine vasculature can be demonstrated by the color and  
pulsed Doppler with detection and analysis of main uterine arteries and their ramifications into  
arcuate and radial arteries upto their spiral artery terminal branches. The blood flow velocity 
increases in the uteroplacental circulation, while its impedance decreases as gestation advances. 
The criteria adopted from studies on uteroplacental circulation for obtaining the flow 
velocity waveform have been distinct. There are reports on evaluation of the arcuate and the 
radial arteries,
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in the uterine artery and arcuate artery on the placental and the contralateral  
sides, besides utilization of average values of right and left uterine arteries.
 
The study of the  
subplacental arteries or the arcuate arteries in just one of the sides of the uterus is not  
representative of the whole uterine flow. The alterations in the placental arcuate arteries appear  
only in more advanced phases of the pathologic processes, and do not allow an early  diagnosis.
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Uterine artery Doppler in normal pregnancy : 
In non pregnant state there is rapid rise and fall in uterine artery flow velocity during 
systole and a “notch” in the descending waveform in early diastole.71 During pregnancy, they 
noted a significant increase in uterine artery compliance between 8 and 16 weeks, which 
continued to a lesser extent until 26 weeks gestation.
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 These changes are reflected in RI and PI 
of uterine artery Doppler signal. 
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Figure 11 - Uterine artery Doppler wave forms 
 
A- Nonpregnant patient.    B- First trimester.     
                 C - Second trimester ,   D- Third trimester     
                E- Abnormal uterine artery Doppler wave form demonstrating high resistance 
38 
Persistence of high impedance to blood flow is observed in the uterine arteries of women 
with PE, which is another indirect evidence of abnormal placentation.
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 It is therefore logical that 
many studies has focused on uterine artery Doppler as a screening test of women at risk of 
developing PE. 
e. Criteria for abnormal test: 
Uterine artery Doppler is considered abnormal when 
PI is > 95
th
 centile (>2.3 in our study- [Both average and single]). 
DOPPLER STUDY OF UTEROPLACENTAL CIRCULATION: 
Using Doppler as a screening test, several studies have demonstrated an association of 
abnormalities in the flow velocity waveform of uterine arteries with subsequent development of 
preeclampsia, IUGR, Placental abruption and preterm delivery. The morphologic changes in the 
uterine vasculature can be demonstrated by the colour, and pulsed Doppler with deduction and 
analysis of main uterine arteries and their ramifications into arcuate and radial arteries upto their 
spiral artery terminal branches. The blood flow velocity increases in the uteroplacental 
circulation, while its impedance decreases as gestation advances.  
The placenta due to its implantation and development, modifies the uterine circulation 
from low flow with high resistance to high flow with low resistance. The abnormal Doppler 
study of the uterine arteries in the early first trimester signifies defective placentation, which is 
detected by the average PI (>2.3). 
Using Doppler ultrasound, the main branch of uterine is easily located at the cervico 
corporeal junction with the help of real time color imaging. Doppler velocimetry measurements 
are usually performed near to its location, either transabdominally or transvaginally, 
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TRANSABDOMINAL TECHNIQUE : 
 Transabdominally, the probe is placed longitudinally in the lower lateral quadrant of the 
abdomen, angled medially. Colourflow mapping is useful to identify the uterine artery as 
it is seen crossing the external iliac artery. 
 The sample volume is placed 1 cm downstream from the cross over point. 
 In a small proportion of cases if the uterine artery branches before the intersection of the 
external iliac artery, the sample volume should be placed on the artery just before the 
uterine artery bifurcation. 
 The same process is repeated for the contralateral uterine artery 
 With advancing gestational age, the uterus usually undergoes dextro-rotation. Thus, the 
left uterine artery does not run as lateral as the right. 
TIMING OF SCREENING 
Screening of PE by uterine artery Doppler assessments is possible from at least 11 weeks 
of gestation. Trophoblastic invasion is maximal in the 1
st
 trimester and PE develops from a 
relative failure of this event, validates the evaluation of uterine artery Doppler assessment in the 
1
st
 trimester.
77
 However screening too early leads to false positive rates and lower PPVs as what 
appears to be abnormal uterine artery Doppler waveforms in early second trimester may fully 
develop and normalize by late second trimester. 
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TRANSVAGINAL TECHNIQUE 
 Transvaginally, the probe is placed in the anterior fornix. Similar to the transabdominal 
technique, the probe is moved laterally to visualise the paracervical vascular plexus and 
the above steps are carried out in the same sequence as for the transabominal technique. 
 The measurement should be repeated independently for the right and the left utrine 
arteries, The average of both is taken and the risk is assessed. 
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REVIEW OF LITERATURE 
 In 1995, van den Elzen et al,83 reported on 352 women aged 35 years and older. Using 
Doptek, the PI was measured at 12 to 13 weeks of gestation, and this was associated with 
the development of hypertensive disorders and FGR. When the PI was in the upper 
quartile the risk of PE was increased by a factor of four when compared to women in 
which PI was in the lower quartile.  
 Martin et al,80 conducted the the largest screening multicenter study to date. 
Transabdominal examination of the uterine arteries was carried out at 11 to 14 weeks in 
unselected population. The sensitivity of mean uterine artery PI above 95
th
 percentile 
(2.35) was 27.0% for PE. The study showed that early diastolic notches were present in 
55% of cases, limiting their use for screening at this gestation. The sensitivity for 
complications requiring delivery before 32 weeks was 60%. 
 In the study conducted by Gomez et al,65  where 999 pregnant women were examined 
between 11 to 14 weeks during routine scan using transvaginal color and pulsed Doppler. 
The authors found a significant change in the 95
th
 percentile of mean uterine artery PI 
with advancing gestation. They reported a progressive decrease in the prevalence of 
bilateral notching and PI with gestation. There were 22 cases of PE, and using a cut-off of 
PI above the 95
th
 percentile, the sensitivity, specificity, PPV and NPV were 245, 95.1%, 
11.3% and 97.9% respectively. The authors of the study acknowledged the potential 
advantages of early screening for PE and associated complications, but concluded that 
there is a limited role for uterine Doppler velocimetry in identifying the pregnancies with 
increased risk of developing hypertensive disorders.  
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 In the prospective study conducted by Pilalis et al,84  878 women were undergone routine 
prenatal ultrasound examination at 11 to 14 weeks, pulsed wave Doppler was used to 
obtain uterine artery flow velocity waveforms and mean PI of the uterine arteries was 
calculated and maternal serum samples for PAPP-A were assayed. The sensitivity of 
mean uterine artery PI > 95
th
 percentile in predicting PE and abruption were 23.1% and 
42.8%% respectively. The authors noted that independent predictors of subsequent 
development of  PE were mean uterine artery PI > 95
th
 percentile and maternal history of 
PE/ hypertension. Increased uterine artery PI was the only independent factor in the 
prediction of placental abruption. The combination of uterine artery PI and maternal 
history of PE/ hypertension was better predictor tha using uterine Doppler alone in 
predicting PE. 
 Plasencia et al,85 investigated the performance of screening for PE using maternal 
characteristics such as body mass index, age, ethnic origin, smoking, medical and 
obstetric history and uterine artery PI in the first trimester. They concluded that in 
unaffected individuals log MoM PI was influenced by maternal ethnic origin, body mass 
index, previous history of PE and fetal crown-rump length. In the prediction of PE 
significant contributions were provided by log MoM PI, ethnic origin, body mass index 
and previous and family history of PE. They also added that for a false-positive rate of 
10% the predicted detection rate of PE requiring delivery before 34 weeks was 82%, 
compared to 31% for late PE, 12% for gestational hypertension and 18% for small for 
gestational age. 
  Harrington et al,86  conducted a follow up study in 652 women with singleton 
pregnancies who had transvaginal uterine artery and umbilical Doppler examination 
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performed at 12-16 weeks of gestation. Measurements include presence/absence of an 
early diastolic notch, vessel diameter, RI, PI, time averaged mean velocity, maximum 
systolic velocity and volume flow in the right and left uterine arteries and RI and PI in 
umbilical arteries. They concluded indicative of a failure to modify the uterine artery 
circulation in early pregnancy are associated with premature delivery(odds ratio 2.38), 
development of PE(odds ratio 42.82)and SGA baby(odds ratio 8.61). 
 Melchiorre et al, conducted a study in 3058 singleton pregnant women at 11-14 weeks of 
gestation. They measured mean RI and presence of early diastolic notch was recorded. 
They concluded that sensitivity and specificity of RI > 95
th
 centile was 24.2% and 95.8% 
respectively in predicting preterm-PE. Early diastolic notch was present in 44.7% of 
normal pregnancies so cannot be used for screening. There were no significant 
differences in first-trimester mean uterine artery RI (P = 0.136) or prevalence of bilateral 
notches (P = 0.459) between women who had a normal pregnancy outcome and those 
who developed pre-eclampsia at term. These data demonstrate that increased uterine 
artery RI in the first trimester is associated with the development of preterm, rather than 
term, pre-eclampsia and provide supportive evidence for the hypothesis that these 
disorders may have different etiologies.
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PREVENTION OF PREECLAMPSIA 
Prevention of PE, if possible, would be a great  in antenatal care. 
Primary prevention: Avoiding the occurrence of the disease by avoiding the risk factors. 
44 
Secondary Prevention: Allows breaking off the disease process before the emergence of 
obvious clinical disease i.e, Early diagnosis and treatment. 
Tertiary Prevention: Prevention of complications caused by the disease process i.e treatment. 
PRIMARY PREVENTION: 
Primary Prevention may be possible to some extent by the modification of some of the 
risk factors  of  PE. As the disease occurs more often in nulliparous women or in multiparous 
women with change of partners, there appears to be a protective effect of long term sperm 
exposure on the frequency of the disease. Hence, it is recommended to have pregnancies with 
low-risk men, to stay with the same partner and to have children at an age when the endothelium 
is still able to cope with the inflammatory stress associated with pregnant state. Prevention or 
effective treatment of obesity could result in a significant reduction in the frequency of PE and 
should be encouraged. Similarly, women with Diabetes, Chronic Hypertension, renal and other 
medical disorders should have their primary condition under control before venturing into 
conception.
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SECONDARY PREVENTION: 
Secondary prevention of any disease is feasible if the following 3 basic requirements are 
fulfilled and are available.
 
1. Accurate knowledge of the patho-physiological mechanisms 
2. Availability of effective screening methods 
3. Means of intervention and modification of patho-physiology 
Unfortunately, in-spite of extensive research world-wide, none of the three criteria are 
available for pre-eclampsia to make a strong case for successful secondary prevention. The 
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multi-factorial origin of the disease suggests that it is highly unlikely that there will be a single 
predictive test available in future to predict PE. 
A. Non-Pharmacological Interventions 
B. Nutritional Interventions 
C. Pharmacological Interventions 
A. Non-Pharmacological Interventions 
Bed Rest : It is recommended initially for women at high risk of developing PE  in the hope that 
it reduces oedema and lowers blood pressure by  increasing urinary output. However, bed rest 
was not found to be effective to  prevent  PE , modify the disease, decrease the incidence of pre-
term delivery, low birth weight or the perinatal mortality. In fact, bed rest can be  harmful to 
pregnant women and should not be routinely recommended. 
Life- Style Changes: Regular ante-natal care is mandatory for the prevention and early detection 
of  PE. Job stress including lack of control over work place, timing and frequency of breaks may 
be related to various adverse events including  PE. But no studies confirms the association, more 
research is required in this field. 
Regular Physical Activity: Regular pre-natal exercise may prevent or oppose the progression of 
the disease as suggested by epidemiological studies. The protective effect results from one or 
more of the following mechanisms:
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• Stimulation of placental growth and vascularity 
•  Reduction of oxidative stress 
• Exercise induces reversal of maternal endothelial dysfunction. 
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B. NUTRITIONAL INTERVENTIONS: 
Dietary Sodium Restriction: Although sodium and water retention are universal in pregnancy, 
there are no differences in total body water or serum sodium concentration between women with 
mild or severe PE as compared to gestationally age matched pregnant women without 
hypertension. Dietary sodium restriction has been found to be useful in long-term management 
of  chronic hypertension in men. However, there is no convincing evidence of its efficacy in 
prevention or treatment of hypertension during pregnancy.
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Dietary Protein and Energy Intake : Several nutritional interventions have been suggested to 
prevent PE including increasing protein and energy intake or restricting protein or energy intake 
for obese women. However, a recent overview of randomized trials of nutritional interventions 
during pregnancy reported no benefit of such measures in the prevention of PE.
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Control of Obesity: Although obesity is a known risk factor for superimposed PE, there is no 
evidence that limiting weight gain during pregnancy reduces its occurrence. 
Fish Oils : Inclusion of fish oils in the diet, Eicosapentenoic acid and docosahexanoic acid, was 
shown by some studies to have a protective effect in the preventin of PE. They inhibit the 
synthesis of arachidonic acid.
92
 
In addition, Eicosapentenoic acid competes with arachidonic acid as the the substrate for cyclo-
oxygenase, inhibiting the production of thromboxane A2 by the platelets and producing low 
amounts of physiologically inactive thromboxane-A3. However several multicentric trials failed 
to reduce the risk of PE or FGR. 
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Alcohol Intake: There is no definite evidence that consumption of less than 120 ml of alcohol 
per week causes any adverse effects on pregnancy outcome including fetal  growth. Not evidence 
to suggest alcohol at excess quantities can cause PE.
 
Arginine Supplementation: Few studies have documented that dietary supplementation with L-  
Arginine has been found to be useful in the prevention of PE.
 
But as such there is no strong 
evidence to suggest L-Arginine supplementation prevents PE. 
C. PHARMACOLOGICAL INTERVENTIONS: 
Role of Antihypertensive drugs: It is known that women with pre-existing chronic hypertension 
are at significantly higher risk of developing PE than their normotensive counterparts. The 
various anti-hypertensive medications like Methyldopa, Labetalol and Atenolol have been 
evaluated in various randomized trials for their efficacy in prevention of superimposed PE.
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Critical analysis of all these trials failed to find any reduction in the incidence of PE. 
Role of Diuretics: A meta-analysis of 9 randomised trials using diuretics in pregnancy revealed 
no reduction in the incidence of PE or perinatal mortality, although the incidence of oedema and 
hypertension was reduced.
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 Due to the deleterious effects such as reduced renal and placental 
perfusion, diuretics should not be recommended in PE. 
Zinc Supplementation: Zinc concentration is reduced among women with hypertensive 
disorders of pregnancy.
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 Recent randomized clinical trials have failed to demonstrate the 
efficacy of zinc supplementation for the prevention of PE. 
Magnesium supplementation: Magnesium has a proven benefit for the prevention and 
treatment of severe PE and eclampsia. Hence it was implicated that deficiency of magnesium 
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was important in the pathogenesis of PE.
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 A Cochrane review of two trials could detect no 
apparent effect of magnesium supplementation on the prevention of PE. 
Role of low dose aspirin: The abnormalities of vasospasm, endothelial cell dysfunction and 
activation of coagulation- haemostasis systems are probably caused by an imbalance in the 
production of prostaglandins, PGI2 (vasodilator and inhibitor of platelet aggregation) and TXA2 
(Vasoconstrictor and platelet aggregator), with the balance tilted in favour of TXA2. Low dose 
aspirin (50-150mg /day) therapy during pregnancy selectively inhibits platelet TXA2 
biosynthesis with minimal effects on PGI2 production.
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Multiple clinical trials including the CLASP study concluded that the overall use of low dose 
aspirin in pregnant women was associated with a 12% reduction in the incidence of PE and 19% 
reduction in the pre-term delivery in the high risk group. Thus the only group in whom Low dose 
Aspirin may be justified are those specially at high risk for early onset PE. 
Role of Folic Acid and other B-Vitamins: Women with PE have been shown to have elevated 
levels of homocysteine which occur prior to the onset of the disease. Elevated levels of 
homocysteine may damage the lining of blood vessels leading to signs and symptoms of PE. 
Homocysteine concentrations have also been weakly and negatively correlated with the plasma 
folate concentration.
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 Few trials have so far shown a reduction in the incidence of PE following 
Vitamin B6 and folic acid. Although the metabolic correction of hyper homocysteinemia occurs, 
it is unknown currently whether or not metabolic correction translates into improved perinatal 
and maternal outcome. 
Role of Heparin: Subcutaneous heparin alone or more often in combination with low dose 
aspirin has been used to prevent PE with significant reduction in its incidence. The scientific 
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basis for using heparin
 
 is to modify the endothelial cell dysfunction and the activation of the 
coagulation system, which are central in the  pathophysiology of PE. There is, however, 
insufficient data available to recommend its use routinely in the prevention of PE except in Anti-
phospholipid Syndrome.
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 Moreover, its use can cause adverse reactions like increased chances 
of spontaneous abortion, abruptio placentae, post partum haemorrhage and osteoporosis in the 
mother. 
Calcium Supplementation: Data from epidemiological and observational studies have shown that 
there is an inverse relationship between calcium intake of  2 gms/day and the frequency of  PE  
and eclampsia. This effect was greatest in women at high risk of hypertension and those with low 
baseline calcium intake.
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Role of Nitric Oxide Donors: Nitric oxide is a major paracrine mediator released by the 
endothelial cells. It is a potent vasodilator and inhibits platelet aggregation and adhesion to the 
vascular endothelial surfaces. Research indicated that PE is characterized by impaired NO (nitric 
oxide)
 
 synthesis with diminished production of second messenger cyclic guanosine
 
 
monophosphate (cGMP). Small studies have shown the beneficial effects of
 
  Nitric oxide donors 
like transdermal glyceryl trinitrate patch 5mg/day in
 
  improving placental flow and 
uteroplacental perfusion in women with PE. Large multicentric trials are under way in various 
hospitals.
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Role of Antioxidants: Oxidative stress seems to play a major role in the aetiopathogenesis of 
PE. Oxidative stress markers are significantly raised while anti-oxidants are concomitantly 
reduced in maternal tissues, deciduas and placenta. Many trials have been completed with 
promising results. Chappell et.al 
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 identified  high  risk  women  by  history  and  by abnormal  
50 
uterine artery Doppler at 20 weeks. They randomized women at 20 weeks to receive either 1000 
mg of Vitamin C and 400 IU of Vitamin E. There was a significant reduction in the markers of 
endothelial Activation. Plasminogen Activator Inhibitor ratio (PAI-1/PAI-2 ratio) . There have 
been many studies on the role of various antioxidants like vitamin C & E, lycopene, selenium, N-
Acetyl cysteine and garlic in the prevention of PE. The use of antioxidant lycopene 2 mg twice 
daily from 16-20 weeks of gestation and continued treatment until delivery was found to have a 
significant reduction in PE. The incidence of FGR was also significantly lower. Results of larger 
trials are yet to be published.    
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OBSERVATION AND RESULTS 
This is a prospective observational study conducted in 150 women at the Department of 
Obstetrics and Gynaecology, PSG Institute of Medical Sciences and Research centre, 
Coimbatore, Tamil Nadu. Based on the uterine Doppler value, my study population (n – 150) is 
divided equally (each 75) into control and case group. In the case group uterine artery Doppler 
value, both single uterine artery Doppler and average uterine Doppler > 2.3 is considered as 
abnormal. Both the control and case group were followed up throughout the gestation for the 
development of adverse pregnancy outcome such as PE, gestational hypertension, eclampsia, 
IUGR and oligohydramnios. 
                         Table –5 Age wise distribution of the study 
AGE CONTROL CASES TOTAL (%) 
< 20 9 5 14 9% 
21  - 25 32 32 64 43% 
26 – 30 29 27 56 37% 
31 – 35 5 9 14 9% 
> 35 0 2 2 1% 
Total 75 75 
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Figure –12 Age wise distribution of study population 
 
Table –5  and figure 12 show that out of 150 patients studied, 43% were between 21 – 25 
yrs of age in both the groups,39% & 36% were between 26 and 30.There is no significant 
differences between the groups(p>0.05) 
  
< 20 21  - 25 26 - 30 31 - 35 > 35
CONTROL 12% 43% 39% 7% 0%
CASES 7% 43% 36% 12% 3%
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Table –6  Shows the mean age distribution in study group 
Mean Age  with study Groups  
  
Sig 
  
Age 
 
Mean SD 
Std. 
Error 
95% CI for 
Mean 
Minimum Maximum Lower  Upper  
CONTROL 25.2 3.484 0.402 24.4 26 19 34 
 CASES 26.13 3.905 0.451 25.23 27.03 18 39 >0.05 
 
The distribution of ante natal mean age of both the groups had 25.2+/-3.48 & 26.13+/-   
3.91.There is no significant difference between the groups(p>0.05) 
Of the age group distribution the youngest one is 18 years and the eldest women is 39 years. 
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Table – 7 Parity status of the study population 
Parity Control Cases Total (%) 
PRIMI 38 43 81 54% 
MULTI 37 32 69 46% 
Total 75 75 
   
Figure -13 Parity status of study population 
 
Table – 7 and Figure – 13 shows the parity status of the 150 women in the study. Maximum 
women i.e  54% are primigravida . Youngest primi being 18 years and eldest primi is 35 years 
old. 46%  are multi, youngest multi is 21 years and eldest multi is 39 years old. 
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Table –8 Family history of study population 
Family History Control (%) Cases (%) 
YES 5 7% 14 19% 
NO 70 93% 61 81% 
Total 75   75   
 
 
Figure –14  Family history of study population 
 
Table –8  and Figure –14  shows the family history of study population. About  7%  and 
19% of women in control and cases group have significant family history. Family history of 
Diabetes Mellitus(DM), Hypertension(HTN), DM and HTN included in this. There is no 
significant family history of preeclampsia or eclampsia found in these groups.Family history is 
insignificant in my study group for adverse pregnancy outcome. 
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CASES 19% 81%
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Table –9   Medical history of the population in the study 
Other medical History in the Population of the Study Groups 
Medical Disorders Case Control Total 
Over Hypo Thyroid 3 2 5 
Type II DM 1 0 1 
GDM on Diet 4 6 10 
GDM on Drugs 5 2 7 
Chronic Hypertension 1 0 1 
Total 14 10 24 
(%) 19% 13% 16% 
Unaffected 61 65 126 
(%) 81% 87% 84% 
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Figure – 15 Medical history of the population in the study 
 
Table –9  and Figure – 15 shows the medical history of the study population. History of 
other medical disorders such as overt hypothyroid, Type 2 DM, GDM on diet/OHA,Chronic 
hypertension are included. In case group ,1 patient with history of chronic hypertension present. 
There is no significant difference in the case and control group  with the medical history. 
  
Medical Disorders Unaffected
CASE 19% 81%
CONTROL 13% 87%
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Table -10 Previous obstetric history of the study population 
Significant Study Group 
History Control (%) Case (%) 
BOH 1 1% 4 5% 
PE 0 0% 1 1% 
NIL 74 99% 70 93% 
Total 75   75   
 
Figure –16 Previous obstetric history in the study population 
 
Table –10  and Figure –16  shows previous obstetric history in the study population. In 
the study group 3% history of BOH present. In the case group 5% has BOH due to 2 Neonatal 
death and 2 term IUD. 
BOH PE NIL
Control 1% 0% 99%
Case 5% 1% 93%
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Table – 11 Shows Uterine artery Doppler value ranges in both case and control group 
Uterine Artery Doppler Control (%) Cases (%) 
< 1.49 (<50th Percentile) 44 59% 0 0% 
1.5 - 2.29 (>50th - 95th Percentile) 31 41% 0 0% 
≥ 2.3 (≥95th Percentile) 0 0% 75 100% 
Total 75   75   
 
Figure – 17 Shows Uterine artery Doppler value ranges in both control and case group 
 
 
 
 
< 1.49 (<50th Percentile)
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Table –12  Shows the mean of clinical variables in the study group 
 
 
 
 
Mean SD 
Std. 
Error 
95% CI for 
Mean 
Minimum Maximum Sig 
Lower 
Bound 
Upper 
Bound 
U/A L Control 1.40 0.41 0.05 1.31 1.50 0.58 2.28 
<0.001 Cases 2.3 0.65 0.08 2.11 2.41 0.5 4 
Total 1.83 0.69 0.06 1.72 1.94 0.5 4 
U/AR Control 1.45 0.42 0.05 1.36 1.55 0.48 2.26 
<0.001 
Cases 2.3 0.71 0.08 2.13 2.46 0.78 4.6 
Total 1.87 0.72 0.06 1.76 1.99 0.48 4.6 
AVR 
U/A 
Control 1.42 0.33 0.04 1.35 1.50 0.64 2.02 
<0.001 
Cases 2.3 0.45 0.05 2.16 2.37 2.3 4.1 
Total 1.84 0.58 0.05 1.75 1.94 0.64 4.1 
 
Figure –17  shows Doppler clinical variables in the study group. The mean average of 
both right and left uterine Doppler in the control group is 1.42 with its minimum of 0.64 and 
maximum of 2.02.In the case group with mean average of 2.3 with its minimum of 2.3 and 
maximum of  4.1. 
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Table – 13  Number of women in case and control group started on prophylactic  aspirin 
Aspirin Control (%) Cases (%) 
Started  1 1% 23 31% 
Not Started 74 99% 52 69% 
Total 75   75   
 
Figure – 18 Number of women in case and control group started on prophylactic  aspirin 
 
Table – 13 and figure -18- shows that 1% in control group was started on aspirin in view 
of age > 30years. In case group 31% were started on aspirin in view of average uterine artery PI 
more than 95
th
 percentile(> 2.3). 
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Table –14 Association of 2rd trimester abnormality in both group 
2 - Doppler Control (%) Cases (%) 
NORMAL 71 95% 65 87% 
RT-DN+ 0 0% 3 4% 
LT - D N + 0 0% 4 5% 
B/L UA N+ 1 1% 0 0% 
QUIT 3 4% 3 4% 
TOTAL 75   75   
 
Figure –19 Association of 2rd Trimester Doppler abnormality in both group 
 
Table -14 and Figure -19  - Shows association of 2
nd
 trimester Doppler with study group. 
In the control group 71 of had normal dopplers and 1 had bilateral uterine artery Doppler 
notching. Remaining 3 was quit after 1
st
 trimester scan. In the case group 65 of them had normal 
Doppler and 3 & 4 ( total 7) had right and left uterine artery diastolic notching. Out of 7 / 5 were 
started on prophylactic aspirin in the first trimester and 3 of them ended up in having pre-
eclampsia. As compared to comtrol group, there are 2
nd
 trimester Doppler abnormality in women 
who had their 1
st
 trimester Doppler abnormality.Of which 50 % of them ending up in adverse 
pregnancy outcome. 
NORMAL RT-DN+ LT - D N + B/L UA N+
CONTROL 95% 0% 0% 1%
CASES 87% 4% 5% 0%
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Table – 15- Association of 3rd Trimester Doppler abnormality in both group 
3 - Doppler Control (%) Cases (%) 
NORMAL 68 91% 67 89% 
ABNORMAL 1 1% 2 3% 
QUIT 6 8% 6 8% 
Total 75 
 
75 
  
Figure –20  Association of 3rd Trimester Doppler abnormality in both group 
 
Table –15 and  Figure – 20  Shows Third trimester Doppler abnormality was about 1% in 
control and 3% in the  case group. There is no significant difference in both the groups 
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Table - 16   Shows association of IUGR with study group 
IUGR Control (%) Cases (%) 
PRESENT 4 5% 21 28% 
ABSENT 71 95% 54 72% 
Total 75 
 
75 
  
Figure -21  Shows association of IUGR with study group 
 
Table -16 and Figure - 21 Shows association of IUGR in the study group.In the control 
group5% of them had IUGR and in the  case group 28% of  them had IUGR . This shows that 
there is significant outcome in the case group than control group. There are significant cases of 
IUGR in case group for both average and single uterine artery PI ≥2.3. 
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Table – 17  Shows association of Oligohydramnios in the study group 
OLIGO Control (%) Cases (%) 
PRESENT 5 7% 8 11% 
ABSENT 70 93% 67 89% 
Total 75 
 
75 
  
Figure - 22 Shows association of Oligohydramnios in the study group 
 
Table –17  and Figure –22 shows association of Oligohydramnios in the study groups .In 
the control group 7% of them had oligohydramnios and in the case group 11% of them had 
oligohydramnios.There is no significant outcome between these groups. 
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Table –18  Shows association of Gestational Hypertension with the study group 
G.HTN Control (%) Cases (%) 
PRESENT 1 1% 4 5% 
ABSENT 74 99% 71 95% 
Total 75 
 
75 
  
Figure –23 Shows association of Gestational Hypertension with the study group 
 
Table –18 and Figure- 23 shows association of Gestational Hypertension in the study 
groups. In the control group 1% and in the case group 5% of them had Gestational 
Hypertension.. Out of 4, 3 had average uterine artery Doppler more than 2.3(maximum of 2.7) 
and 1 had single uterine artery Doppler abnormality. None of the 4 were started on prophylactic 
aspirin. 
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Table –19  Shows association of Pre-eclampsia in the study groups 
PRE -ECL CONTROL (%) CASES (%) 
PRESENT 0 0% 6 8% 
ABSENT 75 100% 69 92% 
Total 75   75   
 
Figure –24 Shows association of Pre – eclampsia in the study groups 
 
Table –19 and Figure -24 shows association of Pre – eclampsia in the study group. In the 
control group none of them had pre – eclampsia. In the case group 8% of them had preeclampsia 
and none in the control group had PE.Out of 6 , 5 were started on prophylactic aspirin in the first 
trimester for abnormal Doppler and 1 was not started on aspirin. There is significant outcome in 
the case group as compared to the control group. Role of aspirin in the prevention of 
preeclampsia was not much effective. Out of 6, 4 had average uterine artery PI > 2.3 and 2 had 
single uterine artery PI > 2.3. 
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Table – 20 Shows the Abnormal uterine Doppler in the case group and adverse pregnancy 
outcome 
Clinical Variables Total  IUGR OLIGO G+HTN PE Eclampsia 
Single Uterine Artery Doppler 
[Right/Left] with its PI >/=2.3 
42 10 3 1 2 0 
56% 13% 4% 1% 3% 0% 
Average of Right and Left 
Uterine Artery Doppler with its 
PI >/=2.3 
33 11 5 3 4 0 
44% 15% 7% 4% 5% 0% 
                        Total 75 21 8 4 6 0 
                         (%) 100% 28% 11% 5% 8% 0% 
  
Table – 20  Shows the abnormal uterine artery Doppler in the study group and adverse 
pregnancy outcome. Out of 75 in the case group, Single uterine artery Doppler abnormality was 
found in 42 and 33 are with average uterine artery Doppler >2.3. Both of them are associated 
with adverse pregnancy outcome (average PI >2.3 is slightly more than single PI >2.3). 
Figure-25 Shows abnormal uterine Doppler in the case group and adverse pregnancy 
outcome 
 
In the case group the maximum % of adverse pregnancy outcome is with IUGR – 28% 
and least % for G.HTN – 5% and 0% outcome with eclampsia. 
IUGR OLIGO G+HTN PE Eclampsia
Adverse Out come 28% 11% 5% 8% 0%
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Table – 21  Shows various adverse pregnancy outcome in both control and case group 
Clinical Variables Control Cases Sig 
IUGR  6% 28% <0.001 
OLIGO 7% 11% >0.05 
G.HTN 1% 5% >0.05 
PRE ECL 0% 8% >0.05 
 
Figure –26  Shows overall  prevalence of adverse pregnancy outcome in the case group 
 
Table –21  and  Figure -26 shows the prevalence of adverse pregnancy outcome in the 
case group. In the case group the adverse pregnancy outcome was associated with 52 % and 48% 
is normal .Adverse pregnancy outcomes such as IUGR, Oligohydramnios, G.HTN and 
Preeclampsia are included in the study. 
Adverse Pregancy 
Out come
52%
Normal
48%
Prevalence of Adverse Pregancy Outcome
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Figure –27  Association of adverse pregnancy outcome in the study groups 
 
In the case group 52% are associated with adverse pregnancy outcome , but in the control 
group only 19% were associated with adverse pregnancy outcome. Adverse pregnancy outcome 
which were included are IUGR, Oligohydramnios , G.HTN, preeclampsia and Eclampsia.So 
there is significant outcome in the case group as compared to control group.The P value is highly 
significant. 
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Table – 22  Shows gestational age at which the pregnancies were terminated in both the 
groups 
GA (weeks) Control (%) Cases (%) 
<37 weeks 3 4% 12 16% 
> 37 weeks 62 83% 49 65% 
QUIT 10 13% 14 19% 
Total 75   75   
 
Figure –28  Shows the gestational age at which the pregnancies were ended in both the 
groups 
 
Table –22 and figure-28 shows the gestational age at which the pregnancies were 
terminated. In the control group 3 had their delivery < 37weeks in view of preterm labour(2) and 
PPROM(1) ,remaining are > 37weeks. In the case group 12 of them had their deliveries <37 
weeks  
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CASES 16% 65% 19%
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Table –23 Pregnancy  terminated in case & control gp <37weeks 
Pregancy Terminated Case (%) Control (%) 
S.PRE ECLAMSIA 4 5% 0 0% 
G.HTN 3 4% 0 0% 
G.HTN+IUGR 1 1% 0 0% 
S.OLIGO DRAMNIOVS 1 1% 2 3% 
S.IUGR 3 4% 1 1% 
  
3 had preterm labour. The lowest gestational age in the case group at which the 
pregnancy terminated was 33 weeks for severe preeclampsia. 
Figure – 29  Pregnancy terminated in case and control group 
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Patients in the case group has been more induced than in the control group. 
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Table – 24 Shows the range of birth weight in both control and case group 
Birth weight(kg) Control (%) Cases (%) 
< 2.0 0 0% 5 7% 
2.01 - 2.50 4 5% 16 21% 
2.51 - 3.50 50 67% 38 51% 
> 3.50  11 15% 2 3% 
Quit 10 13% 14 19% 
Total 75   75   
 
Table – 25 Shows the mean birthweights(kgs) with the study groups 
Birth 
weight 
[Kgs] Mean SD 
Std. 
Error 
95% CI for 
Mean 
Minimum Maximum Sig Lower Upper 
CONTROL 3.056 0.42591 0.05283 2.9505 3.1615 2.03 3.91 
<0.001 
CASES 2.7329 0.52075 0.06614 2.6007 2.8651 1.34 3.75 
 
Table 24 and 25 - shows the mean birth weight in the study group. The mean birth weight 
in the control group was 3.056kg with minimum birth weight of 2.03kg and maximum weight of 
3.9kg. In the case group the mean birthweight was 2.7kg with minimum birthweight of 1.34kg 
and maximum weight of 3.75kg. 
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Table –26 Association of mode of deliveries with the study groups 
Mode of Deliveies Control (%) Cases (%) 
Elective LSCS 5 7% 6 8% 
Emergency LSCS 16 21% 12 16% 
NVD 33 44% 35 47% 
VAVD 11 15% 8 11% 
Quit 10 13% 14 19% 
Total 75   75   
 
Figure –30 Shows association of mode of deliveries with the study groups. 
 
Table- 26  and Figure -30 shows association of mode of deliveries with the study groups. 
Of the total study group 9% of them have undergone elective c- section for primigravida with 
breech presentation and repeat lscs with history of previous lscs, 23% of  have undergone 
emergency lscs for obstetrical indications. 54% delivered normally and 15% by vaccum assisted 
delivery. 
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Table –27 Summary of all Clinical variables in the study group 
Comparison of cases and control subjects 
Clinical Variables Control Cases Sig 
AGE    
Mean +/-SD 25.2+/-3.5 26.1+/-3.9 >0.05 
PARITY    
PRIMI 51%  
>0.05 
MULTI 49%  
FAMILY HISTORY 7% 19% <0.05 
PREVIOUS OBSTERTRIC HISTORY    
BOH 1% 5% 
>0.05 PE 0% 1% 
NIL 99% 93% 
MEDICAL HISTORY 
13% 
 
19% 
 
>0.05 
U/A L    
Mean +/-SD 1.4+/-0.41 2.26+/-0.65 <0.001 
U/A R    
Mean +/-SD 1.4+/-0.41 2.26+/-0.65 <0.001 
AVR U/A    
Mean +/-SD 1.42+/-0.33 2.26+/-0.45 <0.001 
Pregancy Out come 19% 52% <0.001 
GA (weeks)    
< 37 weeks 5% 20% 
<0.05 > 37 weeks 95% 80% 
PREGANCY TERMINATED 4% 16% >0.05 
MODE OF DELIVEIES    
EL - LSCS 8% 10% 
>0.05 
EM - LSCS 25% 21% 
NVD 51% 56% 
VAVD 17% 13% 
BIRTH WEIGHT [kgs]    
Mean +/-SD 3.06+/-0.43 2.73+/-0.53 <0.001 
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Data Analysis - Methods: 
The data are reported as the mean +/- SD or the median, depending on their distribution. 
The differences in quantitative variables between groups were assessed by means of the unpaired 
„t‟ test. Comparison between groups was made by the Non parameteric Mann - Whitney test. 
The chi square test was used assess differences in categoric variables between groups. A 
p value of <0.05 using a two-tailed test was taken as being of significance for all statistical tests. 
All data were analysed with a statistical software package. (SPSS, version 16.0 for windows)  
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DISCUSSION 
Hypertensive disorders of pregnancy are one of the most common complications of 
pregnancy with the incidence of 5 -10%. The associated maternal morbidity, mortality and 
neonatal complications are very adverse indicating the need for early identification of the 
condition preferably before onset of clinical disease. Lot of research has been done and many 
screening options are identified for predicting development of hypertensive disorders in 
pregnancy. But no single screening test is useful. 
Many studies done in second trimester investigated the value of uterine artery Doppler in 
prediction of development of hypertensive disorders of pregnancy, scientific interest is now 
focused on first trimester. This gives the opportunity of early intervention for modifying the 
severity of the disease and meticulous surveillance for early identification of the disease. 
This is a prospective  study conducted at  the Department of Obstetrics and Gynaecology 
at PSG Institute of Medical science and Research centre, Peelamedu, Coimbatore between 
January 2016 – January 2017 with the aim to evaluate the predictive value of first trimester 
uterine Doppler for development of adverse pregnancy outcome.. 
In this study 150 women, representative of local pregnant population irrespective of 
parity are recruited with follow up rate of 100%.  
All the antenatal mothers attending the OPD  between 11 – 13weeks + 6days are chosen 
to perform uterine artery Doppler because a routine NT scan is scheduled in the study population 
at this time of gestation. Based on the uterine Doppler value, my study population (n – 150) is 
divided equally (each 75) into control and case group. In the case group uterine artery Doppler 
value, both single uterine artery Doppler and average uterine Doppler > 2.3 is considered as 
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abnormal and Doppler < 2.2 is considered as control group(normal). Abnormal dopplers in the 
case and normal dopplers in the control group  was  followed up for development of adverse 
pregnancy outcome till delivery. All pregnant women were screened for risk factors such as 
previous obstetric history of preeclampsia, family history of hypertension / diabetes, h/o chronic 
hypertension. 
Uterine artery Doppler indices – Pulsality Index in the first trimester is considered 
abnormal, when PI is >2.3 in both average and single uterine artery Doppler. The exclusion 
criteria were (1) Chronic hypertension (2) Twins (3 )Missed abortion (4) Not consenting. 
Once the abnormal dopplers were found, the patients were closely followed up during 
every antenatal visit for the development of G.HTN, PE , IUGR & Oligohydramnios. They have 
been monitored for the development of abnormality in the 2
nd
 and 3
rd
 trimester dopplers. Both 
case and control group had the same follow up irrespective of normal Doppler values in the 
control group. 
In my study population out of 150 patients studied, 43% were between 21 – 25 yrs of age 
and 37% were between 26 – 30 yrs of age. There is no significant difference between both the 
groups.  
              In my study population  ( 150 no‟s) maximum women i.e  54% are primigravida . 
Youngest primi being 18 years and eldest primi is 35 years old. 46%  are multigravida, youngest 
multigravida  is 21 years and eldest multigravida  is 39 years old. 
In the family history about  7%  and 19% of women in control and cases group have 
significant family history. Family history of Diabetes Mellitus(DM), Hypertension(HTN), DM 
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and HTN included in this. There is no significant family history of preeclampsia or eclampsia 
found in these groups. Family history is insignificant in my study group for adverse pregnancy 
outcome. 
Medical history in the study population such as overt hypothyroid, Type 2 DM, GDM 
OHA. In case group ,1 patient with history of chronic hypertension present. There is no 
significant difference in the case and control group  with the medical history. 
 In the study group ,1% in the control group and 5% in the case group has  BOH due to 2 
Neonatal death and 2 term IUD. Among them none of  have developed hypertensive disorder of 
pregnancy. One of them was diagnosed to have APLA +ve preconceptionally ,for which she was 
started prophylactically on aspirin and heparin. 
Uterine artery Doppler variables in the study population is divided based on the 
abnormality as control and case group. Doppler value in the control group is considered when it 
is < 2.2 and Doppler value in the case group is considered when it is > 2.3 (abnormal) for both 
single  and average uterine artery Doppler. 
In the study population those who had  abnormal uterine Doppler (> 2.3) was started 
prophylactically on aspirin.1% in control group was started  on aspirin in view of age > 30years. 
In case group 31% were started on aspirin in view of average uterine artery PI more than 95
th
 
percentile (> 2.3). 
Follow up of study group for Doppler abnormality in the 2
nd
 and 3
rd
 trimester were 
carried out. There was no significant finding in both control and case group. 
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My study population was followed up for the development of adverse pregnancy outcome 
till delivry such as G.HTN, PE, Oligohydramnios and IUGR. 52% in the case group and 19% in 
the control group were associated with adverse pregnancy outcome. More % of adverse outcome 
in the case group is for IUGR as compared to other variables. 
Gestational age at which  pregnancies were terminated are analysed . In the control group 
3 had their delivery < 37weeks in view of preterm labour(2) and PPROM(1) ,remaining 
delivered  > 37weeks. In the case group 12 of them had their deliveries <37 weeks in view of 
severe PE (4), G.HTN (3), G.HTN+IUGR(1), Severe .IUGR(3), Severe Oligohydramnios(1). 
Birth weight in the study was analysed in both groups. These groups  were categorized as 
very low birthweight(<2kg), low birth weight(2-2.5kg) and normal(>2.5).In the control group 
5% of them had low birth weight and 95% had normal birthweight. In the case group 7% had 
very low birth weight, 21% had low birth weight and 72% of them had normal birthweight. 
Of the total study group 9% of them have undergone elective c- section for primigravida 
with breech presentation  and  repeat lscs with history of previous lscs, 23% of  have undergone 
emergency lscs for obstetrical indications. 54% delivered normally and 15% by vaccum assisted 
delivery. 
Age distribution and parity index were analysed for association of adverse pregnancy in 
the case group. It is evident from the observation  that most of the adverse pregnancy outcome is 
for  reproductive age group between  21-30 years and adverse outcome was more for the 
primigravida in my study population. It is consistent with the study  done by Parra-codero M et 
al,
105
 51% of primigravida developed hypertensive disorders of pregnancy. This shows that 
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nulliparous women who are exposed to paternal antigen for the first time are at increased risk of 
developing hypertensive disorders of pregnancy. 
Other parameters such as family history, previous obstetric history, medical history was 
not significant in my study population. These parameters are considered in my study population 
as reference to the following study - Plasencia et al,
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investigated the performance of screening 
for PE using maternal characteristics such as body mass index, age, ethnic origin, smoking, 
medical and obstetric history and uterine artery PI in the first trimester. They concluded that in 
unaffected individuals log MoM PI was influenced by maternal ethnic origin, body mass index, 
previous history of PE and fetal crown-rump length. In the prediction of PE significant 
contributions were provided by log MoM PI, ethnic origin, body mass index and previous and 
family history of PE. They also added that for a false-positive rate of 10% the predicted detection 
rate of PE requiring delivery before 34 weeks was 82%, compared to 31% for late PE, 12% for 
gestational hypertension and 18% for small for gestational age.But this is contradictory to my 
study. 
      In the present study, abnormal uterine artery Doppler indices(> 95
th
 percentile) noted in 11 -  
13w+6days are compared for their predictive values in the development of adverse pregnancy 
outcome , such as  development of gestational hypertension, PE, eclampsia, IUGR and 
oligohydramnios in the study population and with the available studies which are a few in first 
trimester. 
          Abnormal Doppler value > 2.3(>95
th
 percentile) is taken as cut off as reference to this 
study. In the study conducted by Gomez et al,
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 where 999 pregnant women were examined 
between 11 to 14 weeks during routine scan using transvaginal color and pulsed Doppler. The 
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authors found a significant change in the 95
th
 percentile of mean uterine artery PI with advancing 
gestation. They reported a progressive decrease in the prevalence of bilateral notching and PI 
with gestation. There were 22 cases of PE, and using a cut-off of PI above the 95
th
 percentile, the 
sensitivity, specificity, PPV and NPV were 245, 95.1%, 11.3% and 97.9% respectively. The 
authors of the study acknowledged the potential advantages of early screening for PE and 
associated complications, but concluded that there is a limited role for uterine Doppler 
velocimetry in identifying the pregnancies with increased risk of developing hypertensive 
disorders. 
In the case group out of 75, 56% of them had single uterine artery Doppler(SUAD)  PI > 
2.3 and 44% with average uterine artery Doppler (AUAD)  PI >2.3.Out of 56% in the SUAD 
38% had adverse pregnancy outcome and out of 44%  with AUAD 69.6% had adverse pregnancy 
outcome. In both the groups the maximum adverse outcome was with IUGR. 
Control group has 19% adverse pregnancy outcome, 6% for IUGR, 7% for 
oligohydramnios, 1% fot G.HTN and 0% for PE. Case group has 52% of them had adverse 
pregnancy outcome, 28% for IUGR, 11% for oligohydramnios, 5% for G.HTN, 8% for PE. P 
value is highly significant (<0.001) with case group as compared to control group for adverse 
pregnancy outcome. 
    Thus as compared to control group , case group has significant adverse pregnancy outcome 
On total of the case group 52% of the population has adverse pregnancy outcome in my 
study population. Both average and single uterine artery Doppler >2.3 is significant from my 
study, but average is more significant than single uterine artery Doppler. There were no cases of 
Eclampsia noted in my study population. 
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 There was no studies found which is consistent with single uterine Doppler abnormality 
and adverse pregnancy outcome. The results of which is from my study population.Thus i 
conclude from above that measuring single uterine artery Doppler is also found to be 
significant even if the average is < 2.3. 
 In summary, first trimester uterine artery Doppler in predicting adverse pregnancy outcome 
has advantages such as easily measurable, non invasive , done along with NT scan, can be 
started on prophylactic Loprin, which has some preventive role in adverse pregnancy 
outcome. Close monitoring of these patients result in early diagnosis, thus it reduces both 
maternal and perinatal mortality and morbidity. Thus  above finding suggest that adding 
first trimester uterine artery Doppler to NT scan has great advantage in predicting adverse 
pregnancy outcome. 
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CONCLUSION 
          In pregnancy, hypertensive disorders  are major cause for  maternal and perinatal 
morbidity  and mortality worldwide, particularly in developing countries than developed 
countries. Since, its etiology remains unknown, and there is no effective treatment for this 
complication, the identification of women who are at risk of developing will be of great value. 
This will help us  to  find women who require close antenatal surveillance, allow early referral 
for timely delivery, when signs or symptoms occur. 
Over the span of 12 months , antenatal mothers coming to the OPD  at PSG IMSR  were 
screened for abnormal uterine artery Doppler and those who had abnormal dopplers were closely 
monitored for the development of adverse pregnancy outcome. This early identification of high 
risk women can be helpful for us to start them with prophylactic aspirin which may help in 
modifying disease severity and time of disease occurrence.  
Out of 150 women recuited in the study, 75 each has been divided between case and 
control group. In the case group, out of 75, 56% of them had their single uterine artery Doppler 
adnormality with adverse pregnancy outcome of 38%.Remaining 44% had their average uterine 
artery Doppler PI abnormality, out of which 69.6% of them had adverse pregnancy outcome.The 
maximum  adverse  outcome of my study population is with IUGR. 
The study showed that first trimester uterine artery Doppler  with single and average 
uterine artery PI >95
th
 centile(2.3) has better screening value in my population.  
The overall performance of the first trimester uterine artery Doppler in the prediction of adverse 
pregnancy outcome is valuable. 
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The sensitivity of first trimester uterine artery Doppler can be improved by doing 
combined screening with the maternal characteristics in addition to Doppler changes.  
By identifying the high risk women who has high predictive value for the development 
for adverse pregnancy outcome are closely monitored. Thus it has reduced the incidence of 
maternal and perinatal morbidity and mortality. 
 This can be further improved by addition of other parameters like biochemical markers.   
To conclude from the present study, first trimester Doppler ultrasound is the best non-
invasive investigation to assess changes in uteroplacental hemodynamics which helps in early 
prediction of development of hypertensive disorders in pregnancy along with maternal 
characteristics which helps in  early prophylactic intervention.  
Further research is required to evaluate the generalizability of multiparametric models in 
different resource settings, in addition to assessing the impact of screening on clinical outcomes. 
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INFORMED CONSENT 
PSG Institute of Medical Science and Research, Coimbatore 
Institutional Human Ethics Committee 
INFORMED CONSENT FORMAT FOR RESEARCH PROJECTS 
(strike off items that are not applicable) 
 
I  , DR . ARIVARASI SAI GOKULL RAJ,  am  carrying out a study on the topic: 
         UTERINE ARTERY DOPPLER IN FIRST TRIMEATER (11-13+6WKS) IN PREDICTION OF  
ADVERSE PREGNANCY OUTCOME  
 
as part of my  research project being carried out under the aegis of the Department of :   
OBSTETRICS AND GYNAECOLOGY,  PSG IMSR 
My research guide is: DR. BALASUDHA ,, D.G.O.,DNB,Professor IN Dept of OBG 
 
The justification for this study is:  
       Uterine artery Doppler Waveform analysis has been extensively studied in the second trimester of 
pregnancy as a predictive marker for the late development of pre eclampsia , placental abruption  and fetal 
growth restriction.The use of Doppler interrogation of the vessel in the first trimester has gained momentum 
in identifying the early onset than late onset pre eclampsia. 
 
The objectives of this study are:  
          Correlation of Uterine Artery Doppler in the First Trimester with Adverse pregnancy Outcome. 
 
 Sample size:   150 no’s 
 
Study volunteers / participants are (specify population group & age group): Antenatal patients with single  
                                                      pregnancy  
 
Location: OBG OPD ,PSG IMSR,COIMBATORE 
 
We request you to kindly cooperate with us in this study. We propose collect background information and 
other relevant details related to this study. We will be carrying out:  
 
Initial interview (specify approximate duration):___10__ minutes.  
 
Data collected will be stored for a period of __5_ years. We will / will not use the data as part of another 
study. 
 
Final interview ___10_ mts.   
 
Benefits from this study:  
     1))   Early prediction of later pregnancy outcomes which initiates the early management strategies that 
may    
              prevent or mitigate theses complications. 
     2)  To plan for the timing of delivery     
 
Risks involved by participating in this study: NIL 
 
How the results will be used: Can show positive correlation or negative correlation. 
 
  From this we ll able to find the Cut off value of Uterine artery Doppler at first trimester in early prediction of 
adverse pregnancy outcome 
 
If you are uncomfortable in answering any of our questions during the course of the interview / biological 
sample collection, you have the right to withdraw from the interview / study at anytime. You have the 
freedom to withdraw from the study at any point of time. Kindly be assured that your refusal to participate or 
withdrawal at any stage, if you so decide, will not result in any form of compromise or discrimination in the 
services offered nor would it attract any penalty. You will continue to have access to the regular services 
offered to a patient. You will NOT be paid any remuneration for the time you spend with us for this interview 
/ study. The information provided by you will be kept in strict confidence. Under no circumstances shall we 
reveal the identity of the respondent or their families to anyone. The information that we collect shall be 
used for approved research purposes only. You will be informed about any significant new findings - 
including adverse events, if any, – whether directly related to you or to other participants of this study, 
developed during the course of this research which may relate to your willingness to continue participation. 
 
Consent: The above information regarding the study, has been read by me/ read to me, and has been 
explained to me by the investigator/s. Having understood the same, I hereby give my consent to them to 
interview me. I am affixing my signature / left thumb impression to indicate my consent and willingness to 
participate in this study (i.e., willingly abide by the project requirements).  
 
Signature / Left thumb impression of the Study Volunteer / Legal Representative:  
 
 
Signature of the Interviewer with date:      Witness: 
 
Contact number of PI: 9585093324 
 
Contact number of Ethics Committee Office:  During Office hours: 0422 2570170 Extn.: 5818  
                                                                        After Office hours: 9865561463 
 
 
 
 
 
 
 
 
 
 
â. º¡. §¸¡ ÁÕòÐÅì ¸øæÃ¢ ÁüÚõ ¬Ã¡öîº¢ ¿¢ÚÅÉõ, §¸¡¨Å 
ÁÉ¢¾ ¦¿È¢Ó¨Èì ÌØ 
´ôÒ¾ø ÀÊÅõ 
§¾¾¢: 
ÁÕ. «È¢ÅÃº¢ º¡ö §¸¡Ìø Ã¡ˆ, ¬¸¢Â ¿¡ý â. º¡. §¸¡  ÁÕòÐÅì ¸øæÃ¢Â¢ý / 
ÁÕòÐÅÁ¨ÉÂ¢ý Á¸ô§ÀÚ ÁüÚõ ¦Àñ¸û º¢ÈôÒ ÁÕòÐÅ Ð¨ÈÂ¢ý ¸£ú, “´ùÅ¡¾ ¸÷ôÀ ¸¡Ä 
Å¢¨Ç×¸¨Ç §ÀÚ ¸¡Äò¾¢ý ãýÈ¡ÅÐ Á¡¾ò¾¢§Ä§Â (11-13Å¡Ãõ+6¿¡ð¸û) ¸÷ôÀô¨À ¾ÁÉ¢ ¼¡ôÇ÷ 
Š§¸ý ãÄõ ¦¾Ã¢óÐ ¦¸¡ûÙ¾ø” ±ýÈ ¾¨ÄôÀ¢ø ¬ö× §Áü¦¸¡ûÇ ¯û§Çý. 
±ý ¬ö× ÅÆ¢¸¡ðÊ: ÁÕ. À¡ÄÍ¾¡   
 §ÀÃ¡º¢Ã¢Â÷, Á¸ô§ÀÚ ÁüÚõ ¦Àñ¸û º¢ÈôÒ ÁÕòÐÅò Ð¨È 
¬ö× §Áü¦¸¡ûÅ¾ü¸¡É «ÊôÀ¨¼: 
¸÷ôÀô¨À ¾ÁÉ¢ ¼¡ôÇ÷ Š§¸ý ¬ÉÐ þÃñ¼¡ÅÐ ãýÚ Á¡¾ §ÀÚ  ¸¡Äò¾¢ø À¢ýÉ¾¡¸ 
ÅÃìÜÊÂ ¯Â÷ þÃò¾ «Øò¾õ ÁüÚõ º¢ÍÅ¢ý ÅÇ÷îº¢Â¢ø ¾¨¼ §À¡ýÈÅü¨È «È¢óÐ ¦¸¡ûÇ 
¯¾×õ ¸ÕÅ¢Â¡¸ ÀÃÅÄ¡¸ ¬ö× ¦ºöÂôÀð¼Ð. þó¾ ¸ÕÅ¢¨Â Ó¾ø ãýÚ Á¡¾ §ÀÚ 
¸¡Äò¾¢§Ä§Â ÓýÉ¾¡¸ ÅÕõ ¯Â÷ þÃò¾ «Øò¾õ ÁüÚõ ´ùÅ¡¾ ¸÷ôÀ ¸¡Ä Å¢¨Ç×¸¨Ç 
¸ñÎ «È¢ÂÄ¡õ. 
 
¬öÅ¢ý §¿¡ì¸õ: 
Ó¾ø ãýÚ Á¡¾ §ÀÚ ¸¡Äò¾¢ø ¦ºöÂôÀÎõ ¸÷ôÀô¨À ¾ÁÉ¢ ¼¡ôÇ÷ Š§¸ý ÁüÚõ ´ùÅ¡¾ 
¸÷ôÀ¸¡Ä Å¢¨Ç×¸û þÅüÚìÌ þ¨¼§Â ¯ûÇ ¦¾¡¼÷¨À ¬Ã¡ö¾ø. 
¬öÅ¢ø ÀíÌ ¦ÀÚõ ¿À÷¸Ç¢ý ±ñ½¢ì¨¸: 150 
¬öÅ¢ø ÀíÌ ¦ÀÚ§Å¡÷ÁüÚõ ÅÂÐ: ´ü¨È ¸Õ×üÈ ¸÷ôÀ¢É¢ô ¦Àñ¸û 
¬ö× §Áü¦¸¡ûÙõ þ¼õ: ¦ÅÇ¢ §¿¡Â¡Ç¢¸û À¢Ã¢×, Á¸ô§ÀÚ ÁüÚõ ¦Àñ¸û º¢ÈôÒ 
ÁÕòÐÅòÐ¨È, â. º¡. §¸¡ ÁÕòÐÅ ¸øæÃ¢ ÁÕòÐÅÁ¨É, §¸¡ÂÓòà÷ 
þó¾ ¬öÅ¢ø ±í¸Ù¼ý ´òÐ¨ÆìÌÁ¡Ú §¸ðÎì¦¸¡û¸¢§È¡õ. ¿¡í¸û º¢Ä ¾¸Åø¸¨Ç þó¾ 
¬öÅ¢ü¸¡¸ §º¸Ã¢ì¸ ¯û§Ç¡õ. 
¬ö× ¦ºöÂôÀÎõ Ó¨È: ¸÷ôÀô¨À ¾ÁÉ¢ ¼¡ôÇ÷ Š§¸ý ãÄõ ¸÷ôÀô¨ÀÂ¢ý þÃò¾ ¶ð¼ 
¾ý¨Á¨Â «È¢¾ø  
Ó¾ý¨Á §¿÷¸¡½ø: 10 ¿¢Á¢¼í¸û 
þó¾ ¬öÅ¢ø ¸¢¨¼ìÌõ ¾¸Åø¸û 5 ÅÕ¼í¸û À¡Ð¸¡ì¸ôÀÎõ. þó¾ ¾¸Åø¸û §ÅÚ ¬öÅ¢üÌô 
ÀÂýÀÎò¾ô ÀÎõ/ÀÂýÀÎò¾ô À¼ Á¡ð¼¡Ð. 
 
¬öÅ¢ø ÀíÌ¦ÀÚÅ¾¡ø ²üÀÎõ ÀÄý¸û:  
 ¸÷ôÀ ¸¡Äò¾¢ý À¢ýÀÌ¾¢Â¢ø ²üÀÎõ Å¢¨Ä×¸¨Ç ÓýÉ¾¡¸§Å ¸½¢òÐ «¾ü¸¡É 
º¢¸¢î¨º ¦ºöÅ¾¢ý ãÄõ Àì¸ Å¢¨Ç×¸¨Ç ¾Îò¾ø «øÄÐ Ì¨Èò¾ø. 
 ÌÆó¨¾ À¢ÈôÀ¢ý §¿Ãò¨¾ ¾¢ð¼Á¢Î¾ø. 
 
¬öÅ¢ø Àí§¸üÀ¾¡ø ²üÀ¼ì ÜÊÂ «¦ºª¸Ã¢Âí¸û / Àì¸ Å¢¨Ç×¸û: þ¾É¡ø ±ó¾ 
«¦ºÇ¸Ã¢Â§Á¡, Àì¸ Å¢¨Ç×¸§Ç¡ ²üÀ¼¡Ð.  
¬öÅ¢ý ÓÊ×¸û ±ó¾  Ó¨ÈÂ¢ø ÀÂýÀÎò¾ôÀÎõ? 
¬öÅ¢ý ÓÊ×¸û, À¢ü¸¡Äò¾¢ø ´ùÅ¡¾ ¸÷ôÀ ¸¡Äò¾¢ø ²üÀÎõ Å¢¨Ç×¸¨Ç §ÀÚ ¸¡Äò¾¢ý§À¡Ð 
Ó¾üÀÌ¾¢Â¢§Ä§Â «È¢óÐ ¦¸¡ûÅ¾üÌõ «¾ü¸¡É «Îò¾ ¸ð¼ ÁÕòÐÅ º¢¸¢î¨º ÓýÉ¾¡¸§Å 
«Ç¢ôÀ¾üÌõ ¯¾ÅôÀÎõ. 
 
þó¾ ¬öÅ¢ý §¸ûÅ¢¸ÙìÌ À¾¢ÄÇ¢ôÀ§¾¡, þÃò¾ Á¡¾¢Ã¢¸û «øÄÐ ¾¢Í Á¡¾¢Ã¢¸û ±ÎôÀ¾¢§Ä¡ 
¯í¸ÙìÌ ²§¾Ûõ «¦ºÇ¸Ã¢Âí¸û þÕó¾¡ø, ±ó¾ §¿Ãò¾¢ø §ÅñÎÁ¡É¡Öõ ¬öÅ¢Ä¢ÕóÐ 
Å¢Ä¸¢ì¦¸¡ûÙõ ¯Ã¢¨Á ¯í¸ÙìÌ ¯ñÎ. ±ô¦À¡ØÐ §ÅñÎÁ¡É¡Öõ ¬öÅ¢Ä¢ÕóÐ Å¢ÄÌõ 
¯Ã¢¨Á ¯í¸ÙìÌ ¯ûÇÐ. ¬öÅ¢Ä¢ÕóÐ Å¢Ä¸¢ì¦¸¡ûÅ¾¡ø ¯í¸ÙìÌ «Ç¢ì¸ôÀÎõ º¢¸¢î¨º 
Ó¨ÈÂ¢ø ±ó¾ Å¢¾ À¡¾¢ôÒõ þÕì¸¡Ð ±ýÚ ¯í¸ÙìÌ ¯Ú¾¢ÂÇ¢ì¸¢§È¡õ. ÁÕòÐÅ Á¨ÉÂ¢ø 
§¿¡Â¡Ç¢¸ÙìÌ «Ç¢ì¸ôÀÎõ §º¨Å¸¨Ç ¿£í¸û ¦¾¡¼÷óÐ ¦ÀÈÄ¡õ. þó¾ ¬öÅ¢ø Àí§¸ü¸  
´ôÒì¦¸¡ûÙÅ¾¡ø §ÅÚ ±ó¾ Å¢¾Á¡É ÜÎ¾Ä¡É ÀÄÛõ ¯í¸ÙìÌì ¸¢¨¼ì¸¡Ð. ¿£í¸û 
«Ç¢ìÌõ ¾¸Åø¸û þÃ¸º¢ÂÁ¡¸ ¨Åì¸ôÀÎõ. ¬öÅ¢ø Àí§¸üÀÅ÷¸û ÀüÈ¢§Â¡ «Å÷¸û 
ÌÎõÀò¨¾ô ÀüÈ¢§Â¡ ±ó¾ò ¾¸ÅÖõ ±ì¸¡Ã½õ ¦¸¡ñÎõ ¦ÅÇ¢Â¢¼ôÀ¼¡Ð ±ýÚ 
¯Ú¾¢ÂÇ¢ì¸¢§È¡õ. ¿£í¸û «Ç¢ìÌõ ¾¸Åø¸û / þÃò¾ Á¡¾¢Ã¢¸û / ¾¢Í Á¡¾¢Ã¢¸û «í¸£¸Ã¢ì¸ôÀð¼ 
¬öÅ¢üÌ ÁðÎ§Á ÀÂýÀÎò¾ôÀÎõ. þó¾ ¬ö× ¿¨¼¦ÀÚõ ¸¡Äò¾¢ø ÌÈ¢ôÀ¢¼ò¾Ìó¾ Ò¾¢Â 
¸ñÎÀ¢ÊôÒ¸û «øÄÐ Àì¸ Å¢¨Ç×¸û ²Ðõ ²üÀð¼¡ø ¯í¸ÙìÌò ¦¾Ã¢Å¢ì¸ôÀÎõ. þ¾É¡ø 
¬öÅ¢ø ¦¾¡¼÷óÐ ÀíÌ ¦ÀÚÅÐ ÀüÈ¢Â ¯í¸û ¿¢¨ÄôÀ¡ð¨¼ ¿£í¸û ¦¾Ã¢Å¢ì¸ ²ÐÅ¡Ìõ. 
 
¬ö×ìÌðÀÎÀÅÃ¢ý ´ôÒ¾ø: þó¾ ¬ö¨Åô ÀüÈ¢Â §ÁüÜÈ¢Â ¾¸Åø¸¨Ç ¿¡ý ÀÊòÐ «È¢óÐ 
¦¸¡ñ§¼ý / ¬öÅ¡Ç÷ ÀÊì¸ì §¸ðÎò ¦¾Ã¢óÐ ¦¸¡ñ§¼ý. ¬öÅ¢¨Éô ÀüÈ¢ ¿ýÈ¡¸ô ÒÃ¢óÐ 
¦¸¡ñÎ þó¾ ¬öÅ¢ø ÀíÌ ¦ÀÈ ´ôÒì¦¸¡û¸¢§Èý. þó¾ ¬öÅ¢ø Àí§¸üÀ¾ü¸¡É ±ÉÐ 
´ôÒ¾¨Ä ¸£§Æ ¨¸¦Â¡ôÀÁ¢ðÎ . ¨¸ §Ã¨¸ À¾¢òÐ ¿¡ý ¦¾Ã¢Å¢òÐì ¦¸¡û¸¢§Èý. 
 
Àí§¸üÀ¡ÇÃ¢ý ¦ÀÂ÷, Ó¸ÅÃ¢: 
 
Àí§¸üÀ¡ÇÃ¢ý ¨¸¦Â¡ôÀõ / ¨¸ §Ã¨¸ / ºð¼ôâ÷Å À¢Ã¾¢¿¢¾¢Â¢ý ¨¸¦Â¡ôÀõ: 
 
§¾¾¢ : 
  
¬öÅ¡ÇÃ¢ý ¨¸¦Â¡ôÀõ : 
§¾¾¢  : 
 
¬öÅ¡ÇÃ¢ý ¦¾¡¨Ä§Àº¢ ±ñ: 9585093324 
ÁÉ¢¾ ¦¿È¢Ó¨Èì ÌØ «ÖÅÄ¸ò¾¢ý ¦¾¡¨Ä§Àº¢ ±ñ:  
«ÖÅÄ¸ §¿Ãò¾¢ø0422 2570170 Extn.: 5808 
  «ÖÅÄì §¿Ãò¾¢üÌôÀ¢ý: 9865561463 
 
  
PROFORMA 
Name  :  
Age  : 
S. No.  : 
OP No. : 
IP No.  : 
Unit  : 
Parity Index : 
LMP   :     EDD :  
Gestational Age: 
Menstrual H/o: 
Obstetric H/o: 
Family H/o PIH: 
Mother / Sister 
Medical H/o: 
 None 
 DM 
 HTN 
 APLA 
 Others 
Medication during pregnancy: 
Parameters will be 
monitored 
I - Trimester II - Trimester III - Trimester 
GA by LMP    
GA by VSG    
Growth Disparity    
Doppler 
Study 
 Ut.A    
U.A    
MCA    
BP Monitoring    
Protienuria    
Pre – Eclampsia    
Eclampsia    
Fetal growth restriction    
Ante partum Hemorrhage    
Liquor Volume    
APLA +
ve
    
Abortion (Unexplained)    
Abbreviations:  NA – Not Applicable,  N = Normal   Ut.A – Uterine Artery,  
   UA-Umbilical Artery,  MCA-Middle Cerebral Artery 
 
Pregnancy Outcome  -  Term / Preterm 
Type of Delivery  - Induced / Spontaneous 
Mode of Delivery  - Normal / Caesarean 
If caesarean Section, Indication - 
Intrapartum Complications - Yes / No 
If yes,  
 
 
Baby Details: 
 Sex  : 
Weight : 
APGAR : 
NICU Admission: 
 
          
 
 
ABBREVIATIONS 
S.NO   - Serial Number 
OP NO  - Outpatient Number 
PRE.O.H  - Previous Obstetric History 
FAM H/O  - Family History 
O.MED.H - Other Medical History 
APLA   - Antiphospholipid Antibody 
G.AGE AT D - Gestational Age at Delivery 
MOD   - Mode of Delivery 
G.HTN - Gestational Hypertension 
C.HTN  - Chronic Hpertension 
PE   - Pre ecalmpsia 
IUGR   - Intra Uterine Growth Restriction 
OLIGO  - Oligohydramnios 
GDM   - Gestational Diabetes Mellitus 
GDM  D  - GDM on Diet 
GDM OHA  - GDM on Oral Hypoglycemic Index 
BOH   - Bad Obstetric History 
IUD   - Intra Uterine Death 
NND   - Neonatal Death 
RHD   - Rheumatic Heart Disease 
TM   - Term 
F – Father  ;  M – Mother 
N – Not Started ; Y – Started 
LT  DN +   -  Left Uterine Diastolic Notch present 
RT  DN +   -  Right Uterine Diastolic Notch present 
B/L UA N+  -  Bilateral Uterine Artery Notch+ 
ABS D FL  - Absent Diastolic Flow 
Ano fts  - Anomalous Fetus 
NVD   - Normal Vaginal Delivery 
VAVD  - Vaccum Assisted Vaginal Delivery 
EM/EL  LSCS - Emergency / Elective  Caesarean Section 
APLA   - Anti Phospholipid Antibody Syndrome 
S.NO OP NUM AGE(yrs) AGE(yrs) PARITY PRE .O.H FAM H/O G.AGE U/A (L) U/A  (R) AVR U/A ASPIRIN 2 - DOPP 3 - DOPP IUGR OLIGO G.HTN PRE - ECL ECLAM HELLP APLA O.MED.H GAGE@D MOD B.WT
1 10/11495 22 22 P Nil Nil 12w+4d 0.9 0.48 0.69 N NL NL A A A A A A ND A 38W+ NVD 3.01
1 15/74037 20 20 G2A1 Nil Nil 12w+4d 1.1 1.2 1.15 N NL QUIT         -         -         -          -         -          -          -          -         -        -          -
1 15/84632 29 29 P Nil Nil 12W+3d 1.47 1.56 1.5 N NL NL A A A A A A ND A 39W+ VAVD 3.2
1 12/85241 23 23 G3P1L1A1 CS Nil 12W+2d 2 1.8 1.9 N NL NL A A A A A A ND A 38W+ EM - LSCS 2.72
1 15/83371 20 20 P Nil Nil 11W+5d 1.98 1.63 1.8 N NL NL A A A A A A ND A 37W+ NVD 2.77
1 15/67194 29 29 G2P1L1 Nil Nil 12W+2d 1.26 1.47 1.36 N NL NL A A A A A A ND A 39W+ VAVD 3.3
1 14/49505 23 23 P Nil Nil 12W+3d 0.85 2.26 1.55 N NL NL A A A A A A ND A 40W NVD 3.32
1 15/84451 20 20 P Nil Nil 12W+5d 2.28 1.2 1.74 N NL NL A A A A A A ND A 38W+ NVD 2.48
1 13/21106 30 30 G2P1L1 G.THN,CS F-HTN 12W+5d 1.73 2.15 1.94 N NL NL A A A A A A ND A 38W+ EL - LSCS 3.91
1 15/85453 21 21 P Nil Nil 12w+4d 1.83 1.8 1.81 N NL NL P A P A A A ND Hypo 38w+ NVD 2.69
1 15/84561 25 25 P Nil Nil 12W+6d 1.52 2 1.76 N NL NL A A A A A A ND A 39W+ VAVD 2.95
1 16/00716 27 27 G2P1L1 Nil Nil 12W+3d 0.58 0.69 0.635 N NL NL A A A A A A ND EMPTY SS 38W+ EM - LSCS 2.03(SGA)
1 16/03603 27 27 G2A1 Nil Nil 13W+5d 1.56 1.8 1.68 N NL NL A A A A A A ND A 40W EM - LSCS 3.19
1 12/17947 26 26 G4P2L1A1 NND,CS F&M HTN 12W+2d 1.18 1.54 1.36  N NL NL A A A A A A ND A 38W+ EM - LSCS 2.75
1 15/80483 27 27 G2A1 Nil Nil 11W+5d 0.76 1.03 0.89 N NL NL A A A A A A A A QUIT         -           -
1 15/86401 34 34 G2P1L1 Nil Nil 12W+5d 1.96 1.9 1.9 N NL NL A P A A A A A GDM - D 40W EM - LSCS 3.7
1 14/19430 31 31 G2P1L1 Nil Nil 13W+5d 1.72 0.84 1.28 N NL NL A A A A A A A A 40W NVD 3.29
1 15/83248 22 22 P Nil Nil 12w+4d 1.53 1.11 1.32 N NL NL A A A A A A A A 39W+ NVD 3.11
1 15/49755 28 28 G1A1 Nil Nil 12wks 1.2 1 1.1 N QUIT          -         -         -         -         -          -         -                  -          -         -         -          -
1 15/85169 24 24 P Nil Nil 13w+4d 2.13 1.57 1.85 N NL NL A A A A A A A GDM - D 40W EM - LSCS 3.3
1 15/65397 21 21 G2A1 Nil Nil 12wks 2.17 1.87 2.02 N NL NL A A A A A A A A 40W VAVD 3.1
1 12/77298 26 26 P Nil Nil 12w+5d 1.09 1.15 1.12 N NL NL A A A A A A A A 39W+ VAVD 3.12
1 13/19418 27 27 G1P1L1 Nil M&F HTN 11w+4d 2.06 1.54 1.8 N NL NL A A A A A A A A 40w VAVD 2.97
1 16/01405 23 23 P Nil Nil 13wks 1.6 1.3 1.45 N NL NL A A A A A A ND A 40W NVD 2.83
1 15/86985 20 20 G3A2 Nil Nil 11w+5d 1.19 1.28 1.23 N NL QUIT         -           -         -         -          -          -        -         -          -         -           -
1 15/29237 29 29 P Nil Nil 12W+2d 1.2 1 1.1 N NL NL A A A A A A ND A 40W VAVD 3.2
1 15/86325 25 25 P Nil Nil 11w+6d 2 1.6 1.8 N NL NL A A A A A A ND A 40W NVD 3.27
1 15/87244 24 24 P Nil Nil 12W+5d 1.4 1.2 1.3 N NL NL A A A A A A ND GDM - D 40w NVD 3.78
1 15/87376 23 23 P Nil Nil 12w+4d 1.5 2 1.75 Y B/L UA N+ NL A A A A A A ND A 37W+ NVD 2.5
1 16/05954 25 25 P Nil Nil 12w+5d 1.4 2.18 1.79 N NL NL A A A A A A ND A 40W EM - LSCS 3.36
1 16/02294 26 26 G2P1L1 CS Nil 11W+5d 1.8 2 1.9 N NL NL A A A A A A ND A 38W+ EL - LSCS 3.05
1 15/80703 30 30 G2P2L2 CS F - HTN 12W+4d 1.6 2 1.8 N NL NL A A A A A A ND A 38W+ EL - LSCS 3.11
1 15/84607 20 20 P Nil Nil 12W+2d 2 1.73 1.86 N NL NL A A A A A A ND A 38W+ NVD 2.75
1 15/87962 23 23 P Nil Nil 12W+1d 1.4 2 1.7 N NL NL A A A A A A ND Hypo 38W+ NVD 2.94
1 15/85640 30 30 P Nil Nil 13WKS 1.03 1 1 N QUIT          -         -         -           -          -         -         -           -          -         -         -            -
1 14/08870 20 20 G2P1L1 Nil Nil 12W+2d 0.98 0.59 0.78 N NL NL A A A A A A ND A 39W+ EM - LSCS 3.59
1 16/30572 23 23 P Nil Nil 12W+2d 1.1 1.5 1.3 N NL NL A A A A A A ND A 38W+ NVD 2.67
1 16/38101 26 26 P Nil Nil 12WKS 1.62 1.65 1.63 N NL NL A A A A A A ND GDM - DS 38W+ EM - LSCS 3.88
1 16/38374 25 25 P Nil Nil 12W+5d 1 1.7 1.35 N NL NL A A A A A A ND A 37W+ EM - LSCS 2.92
1 16/37165 25 25 P Nil Nil 12wks 0.8 1.5 1.15 N NL NL A A A A A A ND A QUIT         -           -
1 16/36389 25 25 P Nil Nil 12W+1d 1.66 1.7 1.68 N NL NL P A A A A A ND A 39W+ NVD 2.52
1 16/37369 26 26 P Nil Nil 12W+1d 1.1 0.75 0.92 N NL NL A P A A A A ND A 35W+ NVD 2.46
1 14/26201 25 25 G1A1 Molar pg Nil 12W+6d 1 1.2 1.1 N NL NL A A A A A A ND A 40W VAVD 2.68
1 13/73650 27 27 P Nil Nil 12w+4d 1.1 0.9 1 N NL NL A P A A A A ND A 38W+ NVD 2.9
1 16/38342 23 23 P Nil Nil 12WKS 1.2 1.1 1.15 N NL         -         -          -         -          -          -           -          -          -          -          -           -
1 15/74745 23 23 G2A1 Nil Nil 12W+6d 1.18 1.76 1.47 N NL NL A A A A A A ND A 38W+ NVD 2.68
1 14/33264 34 34 G4P2L1A1 BOH,RHD F&M HTN 13W+1d 1.28 1.29 1.28 N NL NL A A A A A A ND A 38W+ NVD 3.04
1 12/52151 22 22 G3P1L1A1 Nil Nil 12W+5d 1.63 2.09 1.845 N NL NL P A A A A A ND A 38W+ NVD 2.6
1 15/43926 25 25 P Nil Nil 12w+4d 2 1.4 1.7 N NL NL A A A A A A ND GDM - D 40W FAVD 3.63
1 11/59065 22 22 G2P1L1 Nil Nil 13Wks 1.25 1.1 1.175 N NL NL A A A A A A ND A 40W NVD 3.67
1 16/02978 33 33 G2P1L1 Nil Nil 12W+1d 1.57 1 1.28 N NL NL A A A A A A ND A        -         -          -
1 16/05770 24 24 G2P1L1 CS Nil 12W+6d 2 1.33 1.66 N NL NL A A A A A A ND A 38W+ EM - LSCS 2.87
1 15/22670 20 20 G2P1L1 Nil Nil 12W+6d 1.9 1.5 1.7 N NL NL A A A A A A ND A 39W+ NVD 2.94
1 16/12495 22 22 G2P1L1 Nil Nil 13Wks 1.3 1.9 1.6 N         -           -        -          -           -          -           -           -          -         -            -          -          -
1 11/23889 26 26 G3P1L1A1 LSCS Nil 12W+6d 1.4 1.4 1.4 N NL NL A A A A A A ND A 39W+ EL - LSCS 3.11
1 16/12550 25 25 P Nil Nil 12W+1d 1.2 1.6 1.4 N NL NL A A A A A A ND A 39W+ VAVD 3.32
1 16/12680 19 19 P Nil Nil 12W+5d 0.62 1.84 1.23 N NL NL A A A A A A ND A 36W+ NVD 2.54
1 14/79019 26 26 G2P1L1 Nil Nil 12W+2d 1.14 1.19 1.165 N NL NL A A A A A A ND A 39W+ EM - LSCS 3.05
1 14/26853 20 20 G2P1L1 Nil Nil 12W+3d 1.4 0.9 1.15 N NL NL A A A A A A ND A 39W+ NVD 3.23
1 16/20523 29 29 P Nil Nil 13wks 1.3 1.59 1.44 N NL NL A A A A A A ND A 38W+ NVD 2.76
1 10/01517 27 27 G2A1 Nil Nil 12W+6d 1.41 0.8 1.1 N NL NL A P A A A A ND DM 38W+ EM - LSCS 2.82
1 13/10943 31 31 G3P1L1A1 Nil Nil 12W+3d 0.68 1.7 1.19 N NL ABS D FL P A A A A A ND A 37W+ NVD 2.52
1 15/77283 23 23 P Nil Nil 12W+3d 1.5 1.9 1.7 N NL NL A A A A A A ND A 38W+ EM - LSCS 3.13
1 07/83662 29 29 P Nil Nil 12w+4d 1.06 1.4 1.23 N NL Ano fts          -          -           -          -          -         -          -          -           -         -          -
1 11/94144 27 27 G2P1L1 Nil Nil 12wks 0.98 1.68 1.33 N NL NL A A A A A A ND GDM - DS 39W+ VAVD 3.65
1 15/77788 27 27 P Nil Nil 12W+5d 1.89 2 1.94 N NL NL A A A A A A ND GDM - D 36W+ NVD 2.3,SGA
1 16/22515 25 25 P Nil Nil 11W+4d 1.71 0.96 1.33 N NL NL A A A A A A ND A 39W+ NVD 3.2
1 16/18821 23 23 P Nil Nil 12wks 1.8 1.4 1.6 N NL NL A A A A A A ND A 40W EM - LSCS 3.87
1 07/63985 29 29 P Nil Nil 12W+5d 1.56 1.16 1.36 N NL NL A P A A A A ND A 37W+ NVD 2.58
1 16/10899 24 24 P Nil Nil 12W+6d 1.63 1.84 1.73 N NL NL A A A A A A ND A 40W EM - LSCS 3.87
1 13/39535 26 26 G2P1L1 Nil Nil 12W+6d 0.69 1.93 1.31 N NL NL A A A A A A ND A 39W+ NVD 3.48
1 13/52758 27 27 G3P1L1A1 Nil Nil 12W+2d 1.1 1.2 1.15 N NL NL A A A A A A ND GDM - D 40W NVD 3.77
1 16/15264 28 28 G2A1 Nil Nil 11w+6d 1 1 1 N NL NL A A A A A A ND A 38W+ NVD 2.93
1 16/25881 22 22 G3P1L1A1 Nil Nil 12w+4d 1.4 1.3 1.35 N NL NL A A A A A A ND A 38W+ NVD 2.68
1 16/20782 27 27 G3P1L1A1             CS Nil 12W+6d 1.1 1.2 1.15 N NL NL A A A A A A ND A 38W+ EL - LSCS 3.08
2 16/18294 25 25                 P             Nil             Nil 11w+5d 3.6 4.6 4.1                Y            NL               NL                  A                 A                  A                 A                 A                 A              ND                 A            35W           NVD 2.15
2 11/39261 27 27 G5P1L1A3             Nil             Nil 11w+6d 2.8 1.8 2.3                Y            NL               NL                 A                P                  A                 A                 A                 A              ND       C.THN         34W+           NVD 2.11
2 14/08459 25 25                 P             Nil             Nil 12w+4d 1.8 2.9 2.35                N             NL                NL                A                A                  P                  A                 A                  A              ND       S.VSD          36W            NVD 2.37
2 16/09140 25 25 G2P2L2              CS             Nil 11w+3d 2.27 2.8 2.5               N             NL ABS D FL                A                 A                  A                 A                 A                  A               ND                A         QUIT                -                -
2 16/15384 24 24                P             Nil              Nil 12w+4d 2.4 2.2 2.3                N             NL                NL                A                A                  A                 A                 A                  A              ND                 A          39W+           NVD 3.03
2 16/18000 25 25                P             Nil             Nil 13 wks 1.7 2.3 2                N             NL                NL                P                A                  A                 A                 A                  A              ND                 A            38W            NVD 2.48
2 16/10874 27 27                P             Nil             Nil 12w+3d 2.49 1.29 1.89                 N             NL               NL                A                A                 A                 P                  A                 A               ND                 A           38W+    EM.LSCS 3.09
2 16/16356 22 22                P             Nil              Nil 12w+2d 2.52 2.25 2.38                 N              NL               NL                A                P                 A                 A                  A                 A              ND    ASTHMA           38W+         VAVD 3.26
2 12/57441 26 26 G3P1L1A1             Nil      F-HTN 13W+1d 2.5 1.1 1.8                N              NL               NL                A                A                 A                 A                  A                 A               ND           Hypo            QUIT                -                -
2 16/18988 33 33 G2P1L1             Nil      M-HTN 12W+3d 1.1 2.5 1.8         Y-Age             NL              NL                A                A                 A                 A                 A                 A               ND GDM - D            38W+          NVD 3.12
2 14/62612 26 26 G2P1L1             Nil              Nil 12W+6d 2.4 1.56 1.98                N              NL              NL                A                A                 A                 A                 A                A               ND                  A           38W+           NVD 3.53
2 16/17404 35 35 G2P2L2              CS F&M-HTN 12W+1d 1.2 2.7 1.95                N              NL               NL                A                A                 A                A                 A                 A              ND GDM-OHA             38W  ELE-LSCS 2.87
2 16/16998 26 26                P              Nil               Nil 11w+6d 3.1 1.57 2.3                N           QUIT                 -                -                  -                 -                 -                  -                 -                  -                  -                 -                 -                 -
2 16/19482 23 23                P              Nil               Nil 12w+5d 1.97 2.3 2.13                N   LT - D N +                NL                A                A                 A               A                 A                 A              ND                 A          39W+   EM.LSSCS 3.25
2 16/19883 39 39 G2P1L1              CS       M-DM 11W+4d 3.9 1.89 2.85                N                NL          QUIT                 -                  -                 -                -                 -                 -                 -                  -                -                  -                 -
2 16/12542 31 31               P              Nil               Nil 11w+4d 2.3 2 2.15                N                NL               NL                 A                A                A                A                A                A             ND                 A          38W+   EM.LSSCS 2.94
2 16/13606 24 24               P              Nil               Nil 12W+5d 2.3 1 1.65                y                NL               NL                 A                A                A                A                A                A              ND                 A           38W+            NVD 2.62
2 16/19190 20 20 G1P2L0         2NND               Nil 12w+2d 2.4 1.5 1.95                N                NL               NL                 A                A                 A                A                A                A                A GM -OHA          QUIT                 -                 -
2 16/21393 24 24 G1P1L1              Nil               Nil 12w+5d 2.8 2.3 2.55                y         QUIT               -                 -                 -                 -                 -                 -                 -                 -                 -                 -                 -                 -
2 16/09994 28 28 G2A1              Nil               Nil 12W+2d 2.3 0.78 1.54                N                NL               NL                 A                A                 A                A                A                A                ND                A           38w+   EM.LSSCS 3.75
2 16/33061 27 27 G2P1L1              Nil               Nil  12+2d 2.3 2 2.15                N                NL               NL                 A                A                 A                A                A                A              ND                 A            38W    EL-LSCS 2.25(SGA)
2 16/36902 23 23                P              Nil               Nil 11w+4d 1.2 3 2.1                N                NL               NL                 A                A                 A                A                A                A               ND                 A             36w            NVD 2.61
2 16/34446 24 24                P             Nil              Nil 12W+2d 2.45 1.95 2.2               N                NL               NL                 A                A                A                A                 A                A               ND                 A             38W           NVD 2.23(SGA)
2 12/56875 26 26 G2P1L1              Nil              Nil 11w+5d 2.07 2.3 2.18               N                NL               NL                 A                 A                A                 A                 A                A               ND GDM - D              39W          NVD 3.03
2 16/372000 25 25               P             Nil              Nil 12w+1d 2.09 3.37 2.73                y                NL               NL                A                 A                 A                A                 A               A              ND                 A            39W         VAVD 2.71
2 16/36312 25 25               P              Nil              Nil 12W+5d 1.8 3.1 2.45               N                NL               NL                A               A                 A                 A                A                A               A              ND GDM-OHA             40W   EM-LSCS 3.45
2 16/36490 29 29 G2P1L1             Nil       M-HTN 12W+2d 2.5 1.08 1.79               N               NL                NL                A                 A                A                A               A               A               ND          Hypo             40W            NVD 3.36
2 15/87542 30 30 G2A1             Nil F-HTN&DM 12W+3d 2.29 2.76 2.5                Y RT-DN+           QUIT                -                   -                 -                 -                 -                 -                 -                 -                -                 -                -
2 16/46761 31 31               P              Nil              Nil 12w+2d 1.4 2.3 1.85                N                NL               NL                A                A                  A                 A                A               A                ND                A           39w             NVD 3.1
2 16/34726 24 24               P              Nil        M-DM 13W+2d 2.3 1.4 1.85                y                NL               NL                A                 A                 A                 A                A               A               ND                A            39W            NVD 3.37
2 16/34982 26 26               P              Nil              Nil 12w+2d 1.96 2.98 2.45                N               NL               NL                A                A                P                 A                A               A                ND                A           36W+           NVD 2.62
2 16/34636 25 25               P              Nil               Nil 12W+5d 2.7 2.8 2.75                Y LT - D N +               NL                P                A                 A                  P                A               A              ND                A          35W+            NVD 1.77(SGA)
2 16/38467 27 27 G3P1L1A1              PE     M-HTN 13W+4d 2.4 1.7 2.05                 Y                NL               NL                 A                A                A                 A                A                A              ND                A         QUIT                  -                  -
2 13/88604 24 24 G3P1L1A1              Nil              Nil 12W+1d 3.58 1.71 2.64                y                NL               NL                 A                A                A                 A                A                A              ND                A           37W+           NVD 2.86
2 08/92696 31 31 G4P1L1A2              Nil      F-HTN 13w+3d 2.26 2.37 2.3                N                NL               NL                 P                A                A                A                A                A              ND                A            34W EM - LSCS 1.57
2 10/01300 32 32 G2P1L1              Nil              Nil 12w+3d 2.89 1.82 2.35                N                NL              NL                 A                A                A                A                A                A               ND GDM-OHA          38W+            NVD 2.78
2 12/31356 27 27 G4P2L1A2   TM - IUD              Nil 12w+2d 2.3 2.1 2.2                Y                NL              NL                 A                A               A                A                A                A              ND                A          38w+            NVD 3.25
2 16/49812 31 31               P              Nil              Nil 12+6d 1.56 3.14 2.35                N                NL              NL                 P                P                A                A                A               A              ND                 A           38W+  EM -LSCS 2.5
2 16/53431 20 20               P              Nil              Nil 12W+2d 2.3 2 2.2                N                NL        QUIT                -                -                -                -                -                            -                 A                -                -                -
2 14/53550 26 26               P              Nil              Nil 13wks 1.2 2.4 1.3                N                NL              NL                P               P                A                A                A               A              ND                 A            39W          VAVD 3.07
2 16/39147 26 26               P              Nil              Nil 11w+6d 2.05 2.3 2.17               N                NL              NL                P               A                P                A                A               A              ND                A            35W  EM -LSCS 1.34
2 10/80652 25 25              P             Nil              Nil 12wks 1.79 2.71 2.25                Y                NL              NL                A               A                A                A                A               A              ND                A            38W           NVD 2.85
2 16/41083 28 28              P             Nil      M-HTN 12W+1d 2.03 3.01 2.52                Y                NL              NL                A               P                A                A               A               A              ND                A            39W           NVD 3.01
2 16/59972 25 25 G3P1L1A1            Nil             Nil 12W+6d 2.3 2 2.15               N                NL              NL               A               A                A                A               A               A              ND GDM - D
2 13/23037 29 29 G2P1L1             CS             Nil 12w+3d 2.6 1.4 2                N                NL              NL                P               A                A                A                A                A              ND                A            37W EM - LSCS 2.35
2 16/38284 25 25                P             Nil             Nil 12w+3d 2.4 1.58 1.99                N RT-DN+              NL                A               A                A                A                A                A               ND                A            36W+          NVD 2.8
2 16/35382 19 19                P             Nil             Nil 12w+4d 1.6 2.3 1.95                N               NL              NL                A               A                A                A                A                A               ND                A            37W+          NVD 2.69
2 16/36312 25 25               P             Nil             Nil 12w+5d 1.8 3.1 2.45                N               NL              NL                A               A               A                A                A                A               NDGDM - OHA           38W EM - LSCS 3.45
2 16/45237 25 25               P              Nil              Nil 12WKS 2.27 2.66 2.46                N               NL              NL                A               A                A                A                A                A               ND GDM - D             39W         VAVD 3.14
2 16/34474 19 19                P              Nil              Nil 12w+4d 0.5 2.5 1.5                N               NL               NL                P                P                A                A                A                A                ND         Hypo             38W           NVD 2.37(SGA)
2 16/57056 26 26                P              Nil              Nil 12w+3d 2.76 0.91 1.83                N                NL               NL                A                 A                A                A                 A                A               ND                 A             37W           NVD 2.79
2 16/16319 26 26                P              Nil              Nil 11w+5d 1.8 2.7 2.25                N                NL               NL                A                A                A                A                A                A               ND                 A             37W         VAVD 3.02
2 16/46761 18 18                P              Nil              Nil 12w+2d 1.4 2.3 1.85                N  QUIT             -             -             -            -           -          -           -          -           -           -          -           -
2 16/44876 24 24 G3P1L1A1              CS              Nil 12w+4d 2 2.8 2.4                N               NL               NL                A                A                A                A                A               A               ND               A            38W EL - LSCS 3.02
2 16/44327 22 22                P              Nil              Nil 12w+4d 1.4 2.8 2.1               N               NL               NL                A                A                A                A                A               A               ND               A            39W            NVD 3.19
2 12/79895 27 27 G2P1L1              CS    M- HTN 13WKS 2.6 4.1 3.35                Y               NL               NL                P                A                A                A               A                A              ND                A            38W EM - LSCS 2.12
2 16/57529 25 25 G2P1L1              CS              Nil 13W+4d 2.58 3.11 2.86                N               NL              NL                P                A                A                A                A                 A              ND                A            37W EL - LSCS 2.73
2 16/20483 32 32 G6P2L0A3         2NND              Nil 12w+4d 2.6 1.54 2.07 Y+HEPAR               NL              NL                P                A                A                A                A                A  DONE - P                P             38W EL - LSCS 2.45(SGA)
2 16/39917 29 29                 P              Nil              Nil 12WKS 2.3 1.91 2.1                N               NL              NL                A                P                A                A                 A                 A               ND                A             40W           NVD 3.21
2 07/38975 24 24 G2P1L1              Nil              Nil 12w+4d 1.1 4 2.58                N               NL              NL               A                A                A                A                 A                A               ND               A             40W           NVD 3.5
2 16/39651 37 37                P              Nil F&M-HTN 11w+5d 2.69 1.8 2.26                 Y              NL              NL               P                A                A                A                A               A              ND               A             38W         VAVD 2.2
2 16/34636 23 23               P              Nil      M-HTN 12w+5d 2.7 2.8 2.75                Y RT-DN+             NL                A                A                A                P                A               A              ND             PE             34W           NVD 1.77
2 12/83000 32 32 G2P1L1             CS       F-HTN 12W+1d 1.64 2.45 2.03               N              NL              NL                A               A                A                A               A               A              ND               A            37W EL - LSCS 3.07
2 16/46325 24 24                 P              Nil              Nil 13WKS 1.3 2.3 1.3               N              NL              NL                A              A               A               A                A               A              ND               A             38W           NVD 2.9
2 11/55357 26 26 G3P2L2              Nil               Nil 13W+1d 2.29 2.4 2.34               N              NL             NL                P               A                A               A               A               A               ND                A   QUIT            -           -
2 16/51363 27 27                P              Nil               Nil 12WKS 2.8 2.7 2.75               N              NL             NL               P               P                P               A                A               A              ND               A             38W           NVD 2.4
2 13/46571 23 23 G2P1L1              Nil               Nil 12W+1d 2.14 2.3 2.22               N              NL Ano fts           -             -             -          -          -            -             -             -              -             -            -
2 16/84981 27 27                P             Nil              Nil 12w+2d 3.71 2.27 2.99                Y             NL             NL                P                A               A                A                A               A             ND                A             38W         VAVD 2.39
2 16/34638 21 21               P            Nil              Nil 12WKS 2.8 2.8 2.8                Y LT - D N +             NL               A                 A              A               P                A               A              ND             PE             33W           NVD 1.7
2 11/75233 22 22 G3P1L1A1            Nil              Nil 12w+5d 4 2.8 3.45               Y              NL             NL              A                A               A                A                A               A             ND                A            40W           NVD 3.19
2 15/89132 24 24               P            Nil              Nil 12w+4d 2.6 2.2 2.4               Y              NL             NL              A                A               A                P               A              A              ND              PE             36W EM - LSCS 2.91
2 15/87279 28 28               P            Nil              Nil 12W+6d 2.9 2.2 2.55               N              NL              NL              P               A               A                A               A              A              ND                A             38W           NVD 2.25
2 15/88236 21 21 G2P1L0           IUD             Nil 12w+4d 2.3 1.4 1.85              N              NL             NL               P                A               A                A               A              A              ND               A             36W           NVD 2.3
2 16/06497 29 29               P             Nil              Nil 13W+1d 2.64 1.8 2.22               N              NL              NL               A               A               A                P               A               A              ND             PE            38W EM - LSCS 2.93
2 15/73097 29 29 G2A1             Nil              Nil  13WKS 1.8 2.5 2.15               Y LT - D N +              NL                P               A                A                 A                A                A               ND               A            38W          VAVD 2.3
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